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Fluorescent imaging technologies that offer new ways to visualise and quantify 
fluorescently labelled molecules are increasing, necessitating the development of 
fluorescent molecules that can efficiently and specifically label targets in vitro and in 
vivo.  
The first aim of this thesis was the study of human neutrophil elastase. Human 
neutrophil elastase is an important enzyme in the regulation of inflammation but if 
over expressed can become part of the cause of inflammation itself. To elucidate this 
dual function and have a greater understanding of this enzyme, an imaging probe for 
neutrophil elastase was designed. Firstly, the syntheses of fluorescently labelled three 
branched dendron core structures were optimised, and studied in neutrophils. The 
selected core structure was functionalised with an elastase specific peptide sequence 
and fluorescently labelled. The probe was specifically cleaved by neutrophil elastase 
in an enzymatic assay and in the presence of activated neutrophils (Chapter 1).  
Fluorescein and rhodamine are dyes that are readily available, are affordable and 
have convenient wavelengths for microscopy and flow cytometry. 
Carboxyfluorescein diacetate N-succinimidyl ester (CFDA-SE) is a commonly used 
fluorescein derivative, widely used in cell proliferation assay. It is mainly used as a 
mixture of isomers and its synthesis is not reported. Herein a short and simple 
synthesis of the two individual isomers of carboxyfluorescein diacetate  
N-succinimidyl ester as well as the equivalent rhodamine variation 
(carboxytetraethylrhodamine N-succinimidyl ester) is reported (Chapter 2). The 
labelling properties of these probes were studied in proliferation assays on mouse 
and human T lymphocytes. 
Finally, the nuclear penetration of the dendron structure combined with nuclear 
localisation sequences (NLS) was investigated. Attachment of nuclear localisation 
sequences to the probe in the presence of fluorescein demonstrated successful entry 
into the nucleus in human alveolar adenocarcinoma cell line (A549) (Chapter 3). 





The world of medicine was truly revolutionised by the discovery of medical imaging 
techniques. Scientists gave doctors the tools to be able to see within the human body. 
Modalities such as X-rays and ultrasound have been used for many years and remain 
major tools for many forms of analysis from broken bones to pregnancy. The 
development of new imaging techniques that are safer, quicker, cheaper and enable 
better visualisation of organs or individual cells are much sought after. 
Fluorescent molecular imaging is an emerging technique involving fluorescently 
labelled molecules that can facilitate the detection and recognition of particular cells 
(e.g. cancer cells). 
In this thesis, the synthesis and study of fluorescent compounds that only emit strong 
fluorescence light in the presence of human neutrophil elastase, an enzyme involved 
in lung inflammation are targeted, as is the synthesis of widely used cell labelling 
fluorophore. New simple synthetic routes leading to purer fluorophores of two 
different colours were developed, and their cell labelling properties investigated. 
Finally the synthesis and study of fluorescent compounds with the ability to penetrate 
cell membranes as well as the nucleus of cancer cells are presented.  
Highly specific fluorescent molecules used in conjunction with imaging techniques 
will in the future, help doctors make more accurate diagnoses of disease as well as 
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: Chemical shift in ppm 
A549: Human adenocarcinomic alveolar basal epithelial cells 
Boc: tert-Butoxycarbony 
CFDA: Carboxyfluorescein diacetate 
CFDA-SE: Carboxyfluorescein diacetate N-succinimidyl ester 
CFSE : Carboxyfluorescein N-succinimidyl ester 
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DCC: Dicyclohexyl carbodiimide 
DCM: Dichloromethane 
dd: Doublet of doublets 
Dde: 1-(4,4-Dimethyl-2,6-dioxacyclohexylidene)ethyl 




DMEM: Dulbecco’s modified eagle medium 
DMF: N,N-Dimethylformamide 
DMSO: Dimethyl sulfoxide 
DSC: N,N’-Disuccinimidyl carbonate 
EDC.HCl: N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
EDTA: Ethylenediaminetetraacetic acid 
EEDQ: N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline 
ELSD: Evaporative light scattering detector 
eq: Equivalent(s) 
ES: Electrospray 
ESI: Electrospray ionisation 
FACS: Fluorescence-activated cell sorting 
FAM: 5(6)-Carboxyfluorescein 
FITC: Fluorescein isothiocyanate 





FRET: Fluorescence (Förster) resonance energy transfer  
FTIR: Fourier transform infrared spectroscopy 
HBTU:  O-Benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-
phosphate 
HEPES: 2-[4-92-Hydroxyethyl)piperazin-1-yl]ethanesulfonic acid 
HFIP:  Hexafluoroisopropanol 
HMPA: 4-Hydroxymethylphenoxyacetic acid 
HNE: Human neutrophil elastase 
HOBt: Hydroxybenzotriazole 
HPLC: High-performance liquid chromatography 
HR: High resolution 
HRMS: High resolution mass spectra 
IMDM: Iscove’s modified dulbecco’s medium 
IR: Infrared 
J: Coupling constant 
m/z: Mass to charge ratio 
m: Multiplet 
MALDI-TOF:  Matrix-assisted laser desorption/ionization – time of flight  
Mp: Melting point 
MS: Mass spectrometry 
mw: Microwave 
NE:  Neutrophil elastase 
NHS: N-Hydroxysuccinimide  
Ninhyrdrin:  2,2-Dihydroxy-l,3,-indandione 
NIR: Near infrared 
NLS:  Nuclear localisation sequence 
NMP: N-Methyl-2-pyrrolidone 
NMR: Nuclear magnetic resonance 
Oxyma: Ethyl 2-cyano-2-(hydroxyimino)acetate 
Pbf: 2,2,4,6,7-Pentamethyldihydrobenzofuran-5-sulfonyl 
PBS: Phosphate-buffered saline 






PeT: Photo-induced electron transfer 
pH: Potentiahydrogenii 
ppm: Parts per million 





Rhodamine B:  Tetraethylrhodamine 
Rho-SE:  Carboxytetraethylrhodamine N-succinimidyl ester 
ROS: Reactive oxygen species 
RP-HPLC: Reverse-phase high-performance liquid chromatography 
rpm: Revolutions per minute 







TFA: Trifluoroacetic acid 
TFE: Trifluoroethanol 
THF: Tetrahydrofuran 
TLC: Thin-layer chromatography 
Trityl:  Triphenylmethyl chloride 
UV: Ultraviolet 
λ: Wavelength 
λem: Emission wavelength 
λex: Excitation wavelength 
Φ: Quantum yield 
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Chapter 1:  
Fluorescence imaging in the life 
sciences 
 
1.1 Fluorescence overview 
Fluorescence and its applications can be seen as a great advancement, if not a 
revolution, in the world of microscopy and cell biology. New technologies which 
utilise fluorescence, united with microscopy have shown how cells are structured. 
Using fluorescence microscopy, scientists have been able to investigate the 
localisation of molecules within the cell including specific genes within a 
chromosome.
6
 The fluorescence revolution has also allowed quantification of 
specific molecules within a cell,
7





 assess cell viability,
11
 study enzyme activities
12
 









 Such discoveries have not been 
contained within the world of fundamental research, and fluorescence technologies 
have now entered the world of medicine at many levels. The work of van Dam 
(2011) illustrates perfectly the possibilities that fluorescence imaging offers in 
medicine (Figure 1).
17
 With the knowledge that ovarian cancer cells overexpress 
folate receptors, an inexpensive fluorescein labelled folate agent was introduced, 
resulting in ovarian cancer cells appearing green while healthy cells remain 




uncoloured, assisting the surgeon in the complete removal of the tumours (Figure 1). 
The procedure itself was quick and yet the application is remarkable. 
 
 
Figure 1: View of the localised region in the peritoneal cavity of an ovarian 
cancer patient as seen with the naked eye (colour image, top left) with the 
aid of fluorescent agent (fluorescence image, bottom left) and the overlay 
(right). Reprinted with permission from Technische Universitaet Muenchen, 
Institute for Biological and Medical Imaging, Faculty of civil engineering and 
surveying medicine. 
 
1.2 Fluorescence principle 
Fluorescence is an emission of light from a substance that is in an electronically 
excited state on relaxation to its ground state.
18
 These states, more commonly known 
as the ground, first, and second electronic states are represented by the terms S0, S1 
and S2 (see Figure 2). At each of these excited states the fluorophore can exist in a 
number of vibrational energy levels. When an electron in a molecular orbital 
belonging to a molecule in its electronic ground state (S0) absorbs energy from a 
suitable light wave, the electron will be promoted to a higher molecular orbital. The 
Overlay color image and 
fluorescence image 




molecule absorbs energy from light and will be raised from the ground state to an 
electronically excited state at various vibrational levels (1), which quickly relaxes to 
the lowest vibrational level of the electronically excited state (S1) (2). It loses this 
excitation energy by transitioning to a lower electronic level through photon 
emission (i.e. fluorescence) (3) or in via a nonradiative decay (quenching) (4). 
 
  
Figure 2: Energy diagram suggested by Jablonski.
19
 1 Excitation of the 
fluorophore through photon absorption, 2 relaxation to lowest vibrational 
state with small loss of energy, 3,5 transition to ground state with 
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The excited state can also undergo forbidden inter-system crossing to the triplet 
excited state where the excitation energy is lost by either photon emission  
(i.e. phosphorescence) (5) or quenching (6).
20
 
There are a variety of processes responsible for quenching, among them are energy 
transfer where the excitation energy is transferred to another molecule, static 
quenching which occurs when there is a stacking interaction resulting in the 
fluorophore forming a non-fluorescent complex,
21
 dynamic and collisional quenching 
which can occur when an excited fluorophore makes contact with a molecule that can 
facilitate non radiative transition to the ground state,
22
 photo-induced electron 
transfer (PeT) (see later),
23




1.3 History of fluorescence techniques  
The earliest description of fluorescence is often associated with the studies of wood 
by Monárdes in the sixteenth century. In 1852 Stokes introduced the word 
‘fluorescence’ describing the light emission induced during excitation and the study 
of numerous fluorescent substances in a one hundred page publication.
24, 25
 It was in 
1871 that the first fluorescent dye, fluorescein, was synthesised by von Bayer.
26
 
Fluorescence was for the first time combined with a microscope in 1911 by the 
physicist Heimstädt.
27
 In 1914, based on this new discovery, von Provazek used a 
fluorescent dye as a stain to enhance the visibility of cells and tissues.
28
 In 1929, 
Ellinger, designed the first epi-fluorescence microscope,
29
 with the light source lying 
on the same side of the sample as the objective, to allow efficient sample excitation, 
and a filter barrier absorbing incident light reflected from the surface of the 








 were made during the following years but it 
was the original confocal microscope, developed and patented by Minsky that had 
the greatest impact.
31
 Its invention introduced a point source of light focused upon a 
specimen. The specimen could move across the focal point of illumination so that a 
selected area of the specimen traverses, and is examined by the point of light. This 
new discovery offered several advantages over standard optical microscopes such as 
reduced blurring of the image from light scattering, improved signal-to-noise ratio, 
increased resolution, clear examination of thick or scattering specimens and x, y and 
z scanning became possible. Although the discovery was at the time astonishing, the 
need for this instrument only came in the late eighties, with the development of 
fluorescently labelled biomolecules.  
In 1941, Coons attached a fluorescent dye (fluoresceinisothiocyanate) to an 
antibody,
32
 to localise its respective antigen in a tissue section. His later studies
33
 
greatly contributed to the use of fluorescent antibodies in research. In 1961, Coons 
wrote "I suggest lightly that this is the hour of the fluorescent antibody”,
34
 without 
knowing that nearly 50 years after its original discovery,
32
 immunofluorescence 




In the mid-eighties the limitations of the optical microscope were obvious, specimen 
thickness being the major inconvenience, it was becoming obsolete.
36
 In 1987 White, 
after reconsideration of the Minsky work, presented the first prototype of a 
commercial laser scanning confocal microscope.
37
 New research could be carried 
out, thicker samples could be analysed as well as three dimensional studies. In 1990 




O’Rourke published the full three dimensional mapping of a specific neuron labelled 
with a fluorescent lipid in the cortex of a tadpole. The study was carried out over 
several days, during which the branching pattern of cell growth could be seen.
38
 
The literature then began to bloom with confocal studies on all sorts of models, with 





 or intracellular localisation of specific nucleic 
acids.
45, 46
 Fluorescent confocal microscopy was widely used for human and rodent 
studies, such as measurements of Ca
2+ 







), and the analysis of other chemical sensors to detect 











 Figure 3 shows a transgenic 
root to illustrate the use of confocal microscopy in a thick sample. Figure 4 shows 
multi stained cancer cells and highlights the ability of the microscope to look at a 
single cell from different angles. 
 
Figure 3: Diagram and confocal image of root tip. a Diagram of Arabidopsis 
root tip and cell divisions (red arrowheads). b Confocal images of the 
SHR:GFP transgenic roots. Scale bars 50 µm. Reprinted with permission 
from Nakajima.
53
 Copyright 2001 Macmillan Publishers Ltd. 
 





Figure 4: Confocal pictures of cancer cells (HeLa), A. stained cell nucleus (blue) and 
stained mitochondria (red), B. stained cell nucleus (blue) and mitochondria-localised 
fluorescent compound (green), C. merged image (orange indicates co-localization), D. 
merged image of the same cell observed from a different angle. Reprinted with permission 
from Yusop.
54
 Copyright 2011 Macmillan Publishers Ltd. 
 
It has now been over twenty five years since the first commercial laser scanning 
confocal microscope and its use in science has not lessened. The field of microscopy 
highlights the uses of fluorescence, but many different techniques have also been 
developed for cellular studies such as fluorescence-activated cell sorting (FACS), a 
machine which allows counting, separation and sorting of cell populations using 
different fluorescent markers;
55
 or the fluorescent microplate reader, an automated 
instrument that can perform complex cell-based assays, reading absorbance or 
fluorescence of up to 1536 samples in parallel. There have been major developments 
in the imaging of whole animals with fluorescence molecular tomography (FMT). 
FMT allows three dimensional imaging of fluorescent markers in whole animal.
56
 
Finally, great improvements in fluorescent imaging agents have been made to 
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1.4 Fluorescent imaging agents 
The design of fluorescent imaging agents is complex requiring many parameters to 
be thought through before any synthesis is carried out. The fluorophore must be 
compatible with the targeted technique and the nature of the biological system, for 
example, excitation in the ultraviolet can cause direct tissue damage,
57
 therefore 
parameters such as wavelength, brightness, stability, target delivery, multiphase 
imaging, and perhaps FDA approval must be considered. The probe itself must be 
planned with the biological target in mind considering parameters such as solubility, 
target specificity and low background fluorescence. 
 
1.4.1 General requirements of the fluorophore 
Wavelength 
A fluorophore must undergo excitation (to reach an excited state), followed by 
emission. Excitation within the blue, green or yellow regions (< 650 nm) have poor 
tissue penetration. Near infrared (NIR) dyes overcome this issue,
58-60
 however, 
commercial NIR dyes often have lower quantum yields than green and yellow dyes 




Brightness of the fluorophore is another important feature. The brighter the dye, the 
less excitation is required, resulting in better signal to noise ratios. The most common 
way to compare fluorophores is to look at their quantum yields Φ, the number of 




photons emitted over the number of photon absorbed with the ideal fluorophore 
coming close to 1.  
Stability 
Another essential property of the dye is its stability in vitro and in vivo. The dye must 
be soluble and stable in aqueous media and not precipitate, aggregate or degrade in 
biological systems. For intracellular studies, photobleaching and dye degradation 
must be considered. Although the dye should be stable long enough for the study to 
be carried out, it must also be degradable to allow excretion, particularly if the study 
aims to be translated to human imaging. 
Target delivery 
The influence of the dye over the targeting moiety is another important 
consideration, even more so when more than one fluorophore per targeting moiety is 
used. Dyes can increase the efficiency of a targeting moiety, for example fluorescein 
has been shown to drive metal complexes into the nucleus,
63
 or on the contrary 
negate a targeting moiety, for example, Cy5.5 dyes (Figure 5) conjugated to a protein 





Figure 5: Generic structure of Cy5.5. 





Using multiple fluorophores that have distinct emission wavelengths is an attractive 
option that fluorescence molecular imaging offers. Multiple targets can be identified 
and followed simultaneously, using different filters to excite and detect the emission 
of each fluorophore. These methods are routinely used in laboratories using confocal 
microscopy or flow cytometry.
65
 Kobayashi (2007) simultaneously imaged five 
separate lymphatic flows in living mice using five different emission wavelengths.
65
 
Multicolour imaging is a fast growing approach with future applications in the field 
of medicine, as it could allow imaging of more than one physiological condition and 
evaluate the pharmacokinetics and interactions of multiple drugs, an asset for drug 
development.
66, 67
 The study of multiple receptors expressed on target cells especially 
for cancer diagnosis,
68, 69
 may increase the understanding of a living tumour or assist 




1.4.2 Targeted fluorescent probes 
Targeted fluorescent probes consist of a fluorophore combined to a targeting moiety. 
Fluorescent labels are powerful tools with broad applications from cellular 
component labelling to biomolecule imaging. All fluorescent targeting probes must 
be non-toxic and able to reach and specifically and efficiently label their target.  
 





Figure 6: Structures of common organelle stains 
 
Some fluorescent labels have been developed to increase the visibility of particular 
organelles such as BODIPY-Ceramide for Golgi apparatus, lyso-trackers for 
lysosomes, DAPI or Hoechst for DNA/nuclei (Figure 7), or mito-trackers for 
mitochondria (Figure 6).
71, 72
 Other well-known dye includes propidium iodide, a 
DNA stain that selectively labels dead cells, a useful tool for cell viability assays.
11, 73
  
Antibodies are common targeting moieties,
74-76
 Figure 7 illustrates this methodology, 
where human epithelial cancer cells were labelled with two fluorescent antibodies 
and a nucleus stain, the extracellular domain and intracellular domain can be easily 
visualised as well as the nuclei. Other biomolecules are also commonly used as 













Figure 7: Human epithelial cancer cells (FaDu) were labelled with two 
specific primary antibodies in combination with fluorescently labelled 
secondary antibodies (green and red). Nuclei were counterstained 
with Hoechst 33342 (blue).The location of the extracellular domain 
(green) and the intracellular domain (red) was revealed using laser 
scanning microscopy. Reprinted with permission from Maetzel.
83
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1.4.3 Smart probes  
Smart probes, are molecules that will emit fluorescence after interaction with the 
subject of interest. They can be classified into three categories: small smart 
molecules that have a particular structure, allowing them to fluoresce or be quenched, 
self-quenching molecules where, for example, close proximity of multiple dyes result 
in quenching with disaggregation restoring the fluorescence; and finally quenched 
molecules where a dark quencher moiety is attached to a dye to absorb its 
fluorescence and detachment of the two results in restored fluorescence.  
Small smart probes 
Small smart probes are varied in term of structure, mode of action and targets. They 
are often target-specific and rarely translatable to a different target. To illustrate the 
principle, a few representative examples will be presented.  




Aminomethylcoumarin (AMC) is a common dye that is fluorescent and 
contains a primary amine group. When this primary amine is coupled to an acid the 
resulting amide modifies the electronic structure of the coumarin molecule which 
renders it non-fluorescent. This quenched probe can then be used to monitor enzyme 





Scheme 1: Aminomethylcoumarin based probe for 
enzyme detection. Amide bond of the non-fluorescent 
amidomethylcoumarin can be enzymatically cleaved to free 
fluorescent aminomethylcoumarine. 
 
Diacetylated fluorescein has no fluorescence until an esterase cleaves the 
acetyl groups to restore fluorescein.
85
 Carboxyfluorescein diacetate N-succinimidyl 
ester (CFDA-SE) is used to label proteins within the cytoplasm and is widely used 
for cell division studies.
1
 
Environmental indicators or chemical sensors are typically small activatable 
molecules that detect biologically relevant species or parameters. For example, in 
1997 Crow synthesised a reduced fluorescein derivative that in the presence of 
reactive oxygen species (ROS) is oxidised to fluorescein, restoring its fluorescence.
86
 
Similarly Seo developed silica nanoparticles functionalised with a fluorescein 
derivative that binds reversibly to copper. When the metal complex is formed the 
fluorescence is altered, allowing imaging of Cu
2+
 in living cells.
15
 Environmental 




indicators allow real-time studies of intracellular events, for the understanding of 




Figure 8: Fluorescein structure divided into two parts, the 
benzoic acid moiety (fluorescence switch) and the xanthene 
moiety (fluorophore), angle between the moieties varies 
depending on the R group switching the fluorescence on or 
off. 
 
Another type of activatable molecule is based on photo-induced electron 
transfer (PeT). In this case, when the fluorophore is excited, an electron is excited to 
a higher energy orbital. This excited state leaves a vacancy in a ground state orbital 
that can be filled by an electron donor, turning off the fluorescence. In the case of 
fluorescein, the xanthene moiety and the benzoic acid moiety sit at a 90° angle 
(Figure 8).
88
 Miura showed that when the angle is modified the resulting molecule 
can be non-fluorescent or highly fluorescent.
89
 Ueno have used this knowledge and 
developed BODIPY derivatives with a benzene moiety that can selectively monitor 
nitrative stress (Figure 9).
4
 Compound NiSPY-1 undergoes nitration in the presence 
of peroxynitrite (ONOO
-
) resulting in the formation of the fluorescent NiSPY-1 N 
(Figure 9). This new strategy of rational design led to the development of numerous 










Self-quenched molecules are designed with multiple fluorophores in close proximity 
resulting in a non-fluorescent probe. The probe can be cleaved by an enzyme, 
releasing the fluorophores; or they can be cell specific, and once internalised in the 
cell, the structure is degraded or unfolded allowing the fluorescence emission. 
A first method is based on Förster resonance energy transfer (FRET), where 
two different fluorophores are used. The fluorophores must be carefully selected as 
the first fluorophore must emit at the wavelength the second fluorophore is excited 
at. The efficiency of this process is strongly distance dependent. In close proximity, 
solely the fluorescence of the second fluorophore will be observed and the first 
fluorophore will be quenched, when separated, both emissions can be detected 
(Figure 10A). This principle has been used in various ways; Yang (2006) 
investigated disulfide bond-reducing activity in endosomal compartments and for 
that purpose built a FRET probe where two fluorophores were linked by a disulphide 
Figure 9: Sensor for imaging nitrative stress. In the presence of ONOO
-
 non fluorescent 
NiSPY-1 undergoes aromatic nitration, the resulting compound NiSPY-1 N is highly 
fluorescent with a quantum yield of 0.687. Reprinted with permission from  
Ueno.
4 Copyright 2006 American Chemical Society. 








FRET probes for enzymatic assays are molecules where the two fluorophores are 
attached at the N- and C-terminus of a specific peptide (or on opposite end of the 
cleavage point) that once recognised by the targeted enzyme is cleaved, freeing the 
two fluorophores from each other (Figure 10A).
98
 
FRET probes have also been designed without a need of cleavage between the two 
fluorophores, solely sufficient distance (Figure 10B). Sato (2002) developed a probe 
where the linker between the fluorophores separates them enough to prevent energy 
transfer and quenching. This link is composed of two domains which, upon 















Figure 10: Representation of self-quenching approaches: A. FRET probe with a 
cleavable linker, B. Intramolecular FRET probe with two complementing domains, C. 
intermolecular FRET probe, D. self-quenched polylysine polymer, E. self-quenched 
tetrameric glycoprotein. 
 
FRET can also be observed intermolecularly, this approach has been particularly 
used to study protein interactions, for example, Azpiazu (2004) studied the 




association of G-protein coupled receptors (GPCRs) (Figure 10C).
100
 Their probes 
consisted of two fluorescently labelled G-proteins. Before activation by GPCRs, the 
two studied proteins bind together, causing the fluorophores to FRET. After 




 Another type of self-quenched molecule is based on a mechanism where 
excited fluorophores of the same type absorb the energy emitted from each other that 
would otherwise have led to an emitted photon. The self-quenching properties of 
several xanthene based fluorophores has been investigated, Valdes-Aguilera (1989) 
have shown that homodimer formation induces shifts in absorbance spectra, resulting 
in the complete quenching of the emission fluorescence signal.
101-104
 The first type of 
construct was developed by Weissleder (1999) and is based on multiple fluorophores 
on a synthetic polymer.
105
 The polymer consists of a poly-L-lysine chain that is 
cleaved by proteases resulting in fluorophore separation and thus dequenching 







 The second type of construct was developed by 
Bradley (2002) and consisted of a dendron structure where the branches are built 
with specific peptide sequences and fluorophores.
116
 The resulting probe is non 
fluorescent or weakly fluorescent due to the close proximity of the multiple dyes but 
once the targeted enzyme recognises and cleaves the specific peptide sequence, the 
fluorophores are released resulting in the restored fluorescence. Advantages such as 
ease of preparation, homogeneity and small size, have allowed the study of proteases 
such as protease endoproteinase AspN, and neutrophil elastase.
116, 117
 




Macromolecules are another approach to self-quenched molecules, as 
demonstrated by Hama (2007), where multiple copies of carboxy-X-rhodamine 
(ROX) conjugated to avidin, a non-covalently bound tetrameric glycoprotein resulted 
in a quenched complex. After internalisation into the cell, the tetramer is broken 




An alternative to fluorophore-fluorophore quenching is the combination of 
fluorophore-dark quencher. Dark quenchers are non-fluorescent molecules that 




Similarly to self-quenched molecules, the FRET principle has also been used 
to construct probes using a fluorophore-dark quencher pair. Farber (2001) 
synthesised a cleavable phospholipid covalently linked to a fluorophore (BODIPY) 
and a dark quencher (dinitrophenyl).
120
 Enzymatic cleavage of the phospholipid 
successfully resulted in de-quenching and detectable fluorescence emission.
120
 Using 
the same concept, many peptides have been used as cleavable linkers, such as Bullok 
(2005) who used a caspase specific peptide to detect apoptosis,
121
 or Bulm (2007) 
who synthesised a cathepsin specific peptide to detect tumours in mice.
122
 
Similarly to self-quenched molecules, avidin was constructed with a 
combination of dark quenchers and fluorophores and upon tetramer digestion within 
lysosomes the fluorescence was restored, resulting in the visualisation of peritoneal 
cavity.
123
 Another example is the design of trastuzumab, a monoclonal antibody 
synthesised with a fluorophore and a dark quencher. Once the antibody is recognised 




and penetrates the cells, its degradation in lysosomes results in fluorescence 
emission, allowing the visualisation of lung tumours.
123
 
Pre-targeting activation is another strategy where two complementary 
imaging agents are used. For example, Ogawa (2008) used a monoclonal antibody 
with a fluorophore and a biotin molecule, after sufficient accumulation of the 
fluorescing antibody to the target, another agent was added.
124
 This agent was a 
combination of a dark quencher and a neutravidin molecule, unbound antibody was 
then bound to the neutravidin−quencher, reducing the background signal. By using 





1.5 Thesis aim 
The aim of this thesis was to contribute to the field of fluorescent imaging agents by 
developing targeted fluorescent probes and activatable imaging probes, as well as 
improving the synthesis and purity of well-known dyes such as fluorescein and 
rhodamine. 
Previously, in the Bradley group self-quenched dendrons were developed. To 
broaden their application and further understand their mode of action, the first aim of 
this thesis was to synthesise and study a “dual-colour” self-quenched dendron for the 
detection of neutrophil elastase. The second aim of this thesis was to establish a 
single isomer synthesis of 5- and 6-carboxyfluoresceindiacetate N-succinimidyl ester 
as well as 5- and 6-carboxytetraethylrhodamine N-succinimidyl ester and study their 
cytoplasm labelling properties. The final aim was to synthesise and investigate the 




nuclear labelling property of the dendron structure when conjugated to nuclear 
localisation sequences. 




Chapter 2:  
Fluorescent probes for the detection 
of neutrophil elastase 
2.1 Introduction 
2.1.1 The immune system 
The immune system is a collection of organs, cells, and molecules with the function 
of protecting the organism against infectious agents. If a microbe enters the body, the 
immune system will react to destroy or contain this invading organism (as well as 
any harmful materials it may produce) using white blood cells and defensive 
peptides.
125
 If the first non-specific attempt at defence is unsuccessful, the system 
will try to adapt and develop a specialised countermeasure. The types of leukocytes 
that perform the first generic defence attempt are produced in the bone marrow, 
predominantly from hematopoietic stem cells.
126
 Stem cells renew themselves 




One of the major distinguishing features between various types of leukocytes is the 
presence or absence of granules. Among the so-called granulocytes are neutrophils, 
eosinophils and basophils. These cells contain distinctive membranes enclosing 
cytoplasmic granules which contain an armoury of enzymes and proteins.
125
 
Neutrophils constitute 50 – 75% of circulating leukocytes, while eosinophils 
represent 1 – 6% and basophils constitute less than 1%.
127
 This large number of 




neutrophils allows them to respond quickly, being the first cell type to be recruited 
by the immune system.  
 
2.1.2 Neutrophils 
The main function of neutrophils is host defence. To fulfil this role, the cell must 
respond to chemical signals generated in the affected tissue, migrate to the site of 
action, recognise and then kill the foreign cells.
128
 They primarily engulf pathogens 
and foreign material by phagocytosis after which bacterial killing is mediated within 
the phagolysosome. The intracellular killing of microorganisms generally involves a 
respiratory burst via non-mitochondrial reduction of oxygen to highly reactive 
oxygen species (ROS). Respiratory burst products and their derivatives include 
superoxide, singlet oxygen, hydrogen peroxide, hydroxy radicals and chloramines.
129
  
As well as performing intracellular mediated pathogen killing, neutrophils have also 
evolved to rapidly degranulate preformed bactericidal products such as ROS and 
cytokines to the extracellular environment.
130
 These released moieties work by 
withholding essential factors that bacteria require to multiply (e.g. iron via the 
release of iron-binding proteins) or by delivering cytotoxic agents (e.g. hypochlorous 
acid) to the bacterium.
129, 131
 There are distinct sets of granules, the so-called 
secondary and tertiary granules, which facilitate neutrophil recruitment to the 
inflammation site and tissue breakdown, and the primary (or azurophilic) granules, 
which can release antimicrobial agents and bactericides.
130
 




Among these antimicrobial agents and bactericides are proteases, the serine protease 
on which this project is focused on is human neutrophil elastase, an enzyme whose 








Neutrophil Elastase (NE) is a 30 kD serine protease glycoprotein consisting of  
218 amino acids. NE has a well-defined catalytic triad of histidine, aspartic acid and 
serine residues.
3
 The X-ray three dimensional structure reported by Korkmaz (2008) 
highlights the catalytic site (Figure 11 in yellow).
3
 Serine proteases bind substrates 
and their active sites hydrolyse peptide bonds very efficiently (Figure 12).
2
 The 
imidazole moiety of histidine deprotonates the hydroxyl group of serine which 
attacks the polarised carbonyl group of an amide bond. The negative charge formed 
on this intermediate is stabilised by hydrogen bond interactions with the protein. 
Following cleavage of the amide bond, an acyl enzyme intermediate is generated 
Figure 11: 3D X-ray structure of NE. Reprinted 
with permission from Korkmaz.
3
 Copyright 2008 
Elsevier Masson SAS. 




along with release of the free amine. Finally, hydrolysis of the ester releases a 






NE is stored in the primary granules at concentrations surpassing the millimolar 
range, making it a major constituent for neutrophils.
133
 NE has been shown to 
contribute significantly to host protection against microbial infections, by 
extracellular killing of micro-organisms.
134
 However, when dysregulated NE can 




2.1.4 Dys-function of neutrophil elastase 
Acute lung injury and the maladaptive repair process that leads to acute respiratory 
distress syndrome (ARDS) are inflammatory diseases. ARDS is characterised by a 
fibroproliferative phase that is phenotypically similar to a condition called idiopathic 
pulmonary fibrosis (IPF), a term that refers to the unknown cause of the disease, 
hence difficulties in diagnosis and treatment, but which can be seen as a dysregulated 
inflammatory and repair response.  
Figure 12: Hydrolysis mechanism in the active site of NE, adapted with permission from 
Hedstrom.
2
 Copyright 2002 American Chemical Society. 




Different mechanisms, by which neutrophil elastase might contribute to the 
inflammation and maladaptive repair seen in ARDS and IPF have been proposed.
136
 
Kawabata (2002) describes different ways NE can preserve its catalytic activity in 
the case of acute lung injury (a simplified figure summarises their proposed 





Figure 13: Proposed mechanism of NE dys-function adapted from Kawabata.
136
 Copyright 
2002 with permission from Elsevier. 
 
Under stimuli, such as acid respiration or pro-inflammatory substances that activate 
neutrophils, NE is released. NE can interfere with epithelial cells and stimulate their 
production of pro-inflammatory cytokines which will activate neutrophils. Activated 
neutrophils will produce NE as well as ROS, which will inactivate the protease 


























To understand more precisely the role of NE in ARDS and/or IPF, there is a need to 
image neutrophil elastase in vivo to be able to measure variation in its activity 
following administration of therapeutics to direct intervention and develop more 
efficacious treatments. 
 
2.1.5 Chapter aim 
This project has the ambition to develop fluorescent probes for the detection of 
neutrophil elastase in vitro.  
 




Bradley has developed an internally fluorescence quenched dendron structure where 
each branch contains a sequence peptide specific to AspN endoproteinase and a 
fluorophore (Figure 14).
116
 This high local concentration of fluorophores results in a 
non-fluorescent molecule which, upon protease cleavage detaches the fluorophores 
from the dendron moiety removing the quenching (Figure 15).  
In this project, the aim was to develop the Bradley strategy further. Firstly, the 
dendron core was to be studied with respect to cell permeability and solubility; 
secondly, peptide sequences specific to neutrophil elastase (Table 1) were added as 
well as a second fluorophore (Figure 15).  
 
 




The targeted peptide sequence was discovered by Korkmaz (2004), it is a nine-mer 
peptide specifically cleaved by NE over two similar serine proteases namely 




Table 1: Specific substrate for NE discovered by Korkmaz
5
 (n.s.h: no significant 
hydrolysis). Reprinted with permission from Kormaz.
5
 Copyright 2013 American 
Thoracic Society. 
 
Korkmaz prepared several substrates and monitored their cleavage by the three 
enzymes using the kinetic parameter kcat/Km, Table 1 illustrates three relevant entries. 
The substrate shown in Entry 9 displays rapid cleavage from elastase but remains 
uncleaved in the presence of proteinase 3 or cathepsin G. A carton of the newly 









n.s.h. <1 11.5±1.5 APEEIMPRQ 10 
n.s.h <1 531±47 APEEIMRRQ 9 
n.s.h 14.6±1.3 683±75 APEEIMDRQ 8 




























Figure 15: Mechanism of action of targeted probes. 




The targeted probe contains peptide sequences specific to neutrophil elastase as well 
as two distinct fluorophores. Due to the dual labelling envisaged, the molecule will 
be traceable before and after enzymatic cleavage, while offering an internal standard. 
Finally it will allow us to follow the dendron moiety once the peptide sequences are 
cleaved and quantify the fluorescence increase during enzymatic cleavage.  
 
2.2 Synthesis of dual labelled dendrons 
2.2.1 Synthesis of the dendron monomer 
 
 
Figure 16: First targeted probe – dual labelled dendron. 
 
The first targeted probe was dual labelled dendron consisting of a dendron core 
moiety, three fluorescein units and a tetraethylrhodamine unit (probe 1 Figure 16).  
In Figure 14 the dendron core structure is highlighted in blue, it was planned to use a 
slightly modified dendron monomer 4 adapted from the dendron moiety 3 published 









Figure 17: Dendron moieties developed by Bradley 2,
116
 Trouche 3 
139
 and newly designed  
monomer 4. 
 
This modification introduces the Dde protecting group, a moiety easy to synthesise 




The synthesis of 1 started with the construction of the three branched dendron 
monomer unit (7). 
 
 
Scheme 2: Michael addition and protection of monomer unit. 
 
The first reaction was a 1,4 addition of the three alcohols of trizma base 5 onto 
acrylonitrile. The reaction was originally carried out in tetrahydrofuran (THF) 
following a literature protocol but yielded just 35% of the desired product rather than 






 Since the reagents were not fully soluble in THF, the yield was 
optimised to 77% using a mixture of water and THF as solvent and an increased 
reaction time of 48 h (Scheme 2). The next step was the protection of the free amine 




Scheme 3: Reduction and orthogonal protection of the monomer. 
 
The next stage of the monomer unit synthesis was the reduction of the nitrile groups 
to the free amine using borane, followed by protection of the resulting free amines 
with 2-(1-Hydroxyethylidene)-5,5-dimethylcyclohexane-1,3-dione (DdeOH) 
(Scheme 3).
141
 The reduction has to be quenched by the sequential addition of acid 
and base.  
 
 
Scheme 4: Hydrolysis of the borazine. 
 




The reason lies in the mechanism explained by Brown.
142
 Once the nitrile groups are 
reduced they form a borazine. The addition of acid hydrolyses the borazine giving 
the amine salt, with the addition of base freeing the amine (Scheme 4). 
 
 
Scheme 5: Synthesis of DdeOH. 
 
The DdeOH protecting group was chosen for various reasons. Firstly, it allows 
orthogonality as the Boc protecting group is removed under acidic conditions to 
which Dde is stable. Secondly Dde is suitable for solid phase synthesis as its removal 
using hydrazine is quick, highly effective, and does not induce cleavage of the linker 
from the resin.  
The synthesis of DdeOH was carried out following a protocol published by Kessler 





Scheme 6: Boc deprotection under acidic conditions. 
 




Once the three branches were Dde protected, the Boc protecting group was removed 
using standard conditions (trifluoroacetic acid (TFA) in dichloromethane (DCM)) to 
give, after a basic wash the free amine product 11 in quantitative yield (Scheme 6). 
 
2.2.2 Linker synthesis 
Modified HMPA linker 
 
 
Figure 18: HMPA linker and Modified HMPA linker 12. 
 
Core resins, such as polystyrene or TentaGel, have by themselves restricted utility 
for peptide synthesis. Thus conditions to allow peptide cleavage from solid supports 
are modulated by the use of linkers. By manipulating the structure of the linker, 
peptides can be cleaved under a variety of conditions ranging from strong to weak 
acids.
143
 The 4-hydroxymethylphenoxyacetic acid (HMPA) linker has good stability 
to a variety of conditions including basic and nucleophilic medium, but can be 
readily cleaved by treatment with trifluoroacetic acid.
143
 The first linker used was a 
modified HMPA to give after cleavage, a free amine as a handle for the attachment 
of a second dye (Figure 18).
144
















Scheme 7: Synthesis of the carbonate 15. 
 
Hydroxybenzaldehyde was reacted with methylbromoacetate under basic conditions 
in the presence of potassium iodide. The reaction was heated at 100 °C and the 
resulting product obtained in high yields (Scheme 7). The aldehyde moiety was 
reduced using sodium borohydride in methanol to give the corresponding alcohol 14. 
Initially, the conversion of the alcohol to the carbonate 15 proved to be difficult. The 
reaction is sensitive to water and nucleophilic solvents such as methanol used in the 
previous step. The compound was obtained by reacting the benzyl alcohol (14) with 
p-nitrobenzyl chloroformate in the presence of pyridine under dry conditions. The 
product could not be purified by extraction but was stable enough to be purified by 
column chromatography (Scheme 7).  
 





Scheme 8: Linker synthesis. 
 
The mono-protected amine TFA salt 16 was given by Thingsoon Jong. The TFA salt 
16 proved to be extremely unstable when neutralised, giving rise to a mixture of 
diaminohexane and the diprotected diamine. Although the migration of Dde groups 
in solution was unexpectedly rapid, it was not surprising as it has been reported to 
occur on solid support.
146, 147
 The mono-Dde protected diamine TFA salt 16 was 
therefore reacted directly with carbonate 15 in the presence of pyridine to obtain the 
stable carbamate 17 (Scheme 8). The methyl ester was hydrolysed to the desired acid 
moiety using 2 M cesium carbonate in methanol and water, (the Dde group is stable 
under these conditions).
148
 The stability of the Dde group during saponification was a 










Scheme 9: Attachment of the linker and monomer onto the resin. 
 
The acid moiety of 12 was converted to the active ester using ethyl 2-cyano-2-
(hydroxyimino)acetate (Oxyma) and N,N′-diisopropylcarbodiimide (DIC) and 
coupled onto amino functionalised TentaGel resin (Scheme 9) with reaction 
completion monitored by the Kaiser test.
150
 A wide variety of coupling reagents have 
been developed for the synthesis of amide bond,
151
 a combination of Oxyma and DIC 
were used as they are a highly efficient combination and have recently been shown to 








Once the linker was attached onto the resin, Dde protecting groups were removed 
using a solution of 4% hydrazine in DMF. The monomer unit 11 was converted to 
isocyanate 4 using Boc anhydride in the presence of DMAP and then attached onto 






Scheme 10: Dye attachment and cleavage from the resin. 
 
Once the dendron moiety was attached onto the linker and Dde groups were removed 
using 4% hydrazine in DMF (Scheme 10). 5(6)-Carboxyfluorescein (FAM) was then 
attached using Oxyma and DIC. Prior to cleavage the construct was washed with 
20% piperidine in DMF in order to cleave any undesired fluorescein esters.
153
 The 




compound 20 was then cleaved from the linker using a trifluoroaceticacid (TFA), 
(Scheme 10) to give the desired compound in poor yield (16%). Since the synthesis 
on solid-phase was short, the yield did not meet expectations. An alternative linker 
that would also allow generation of a primary amine following cleavage was sought. 
The trityl linker was a logical choice and thus the 2-chlorotrityl linker on polystyrene 
resin 21 was chosen.  
Trityl linker 
 
Scheme 11: Spacer attachment. 
 
2-Chlorotrityl linker generates an electrophilic centre when the chlorine leaves. As a 
result the linker is very reactive to nucleophiles including water. As a precaution, the 
synthesis started with the re-activation of the linker using thionyl chloride (Scheme 
11). The pre-activated linker 21 was then reacted with the desired spacer  
1,4-diaminooctane in large excess and at high concentration (5 M). Before each 
reaction, the resin was pre-swollen in dry DCM to ensure maximum penetration of 
the reagents within the beads.  
 





Scheme 12: Dye attachment and cleavage of the probe from the resin. 
 
The freshly prepared isocyanate 4 was then attached onto the spacer. Once again the 
reaction was monitored with the Kaiser test.
150
 Dde protecting groups were removed 
using standard procedures and 5(6)-carboxyfluorescein coupled using Oxyma and 
DIC in DMF (Scheme 12). The final product was obtained after TFA cleavage in 
44% yield. A third route was attempted in order to reduce further the number of steps 
- the construction of the probe entirely in solution (Scheme 13). 
 





Scheme 13: Coupling in solution of the dye. 
 
Attempts to couple 5(6)-carboxyfluorescein (FAM) to 25 were unsuccessful. Three 
coupling reagent combinations were tried to preactivate the acid moiety. The first 
attempt was using 5(6)-carboxyfluorescein and N,N'-dicyclohexylcarbodiimide 
(DCC) in DMF for 20 min followed by addition of the solution to 25. The reaction 
resulted in a complex mixture with no sign of the target compound. The next 
approach was to form the N-succinimidyl ester of the fluorescein, using  
N-hydroxysuccinimide (NHS), DCC and 5(6)-carboxyfluorescein followed by 
addition of the monomer 4. Once again the reaction appeared to be very messy and 
after extensive purification no product was found. The last and final attempt was 
stirring 5(6)-carboxyfluorescein with N-(3-dimethylaminopropyl)-N′-ethyl 
carbodiimide hydrochloride (EDC.HCl) and triethylamine (TEA) in DMF for 30 min 
and the resulting bright red solution added to the monomer. Once again, no desired 
product was found. Different hypothesis as to why the reactions did not work can be 
made with the coupling in solution of 5(6)-carboxyfluorescein being discussed 
extensively in chapter 3. The unprotected phenol groups of fluorescein render all 
couplings in solution difficult. The phenols of fluorescein are known to react with 
active esters, however, on solid phase, undesired fluorescein esters can be cleaved 




using a simple piperidine wash,
153
 with all fluorescein ester by-products that have not 
attached onto the resin being removed by filtration. Further, their formation does not 
impair the reaction as excess of starting material is often used in solid phase 
chemistry.  
 
2.2.3 Dye attachment in solution 
 
 
Scheme 14: Rhodamine coupling in solution. 
 
The final step of the probe synthesis was the attachment of a second dye in solution. 
The second dye chosen was 5(6)-tetraethylcarboxyrhodamine (Rho). Three different 




coupling reagents combinations were carried out. First, the procedure of Liu, using 
NHS and DCC in THF was attempted.
154
 Some of the target product was found but 
only in 8% yield. It was thought that TFA traces from the previous reaction could 
have prevented some amines to react and so, the reaction was repeated after thorough 
removal of the TFA using freeze drying techniques. A base was also introduced but 
in vain. Another procedure from Mukai was attempted.
155
 The procedure involved 
three and a half equivalents of base with HOBt and EDC.HCl. Reaction analyses 
again showed it was extremely messy and yielded no useful products. 
 
 
Figure 19: Reduced isomer combination with single fluorescein labelled target probe. 
 
To overcome this problem, two ideas have been combined. First, a model study will 
be carried out on a commercially available primary amine and 5-(6) 
carboxyfluorescein to screen the best activating agents (Scheme 15). Second of all, a 
monomer unit with a single fluorophore will be first synthesised to simplify analysis. 
Indeed the use of the mixture of isomers 5-(6) carboxyfluorescein on a three branch 
dendrimer can lead to different isomer combinations that are reacted to a mixture of 
isomers of 5-(6) carboxytetraethylrhodamine, giving further possible isomer 
5 or 6 
isomer 
5 or 6 
isomer 
5 or 6 
isomer 
5 or 6 
isomer 
5 or 6 
isomer 




combinations 27 (Figure 19). The new simplified target dendrimer 28 is shown 
Figure 19. 
Model study 
The model study was carried out on benzyl amine and 5(6)-carboxyfluorescein. The 
different conditions used are summarised in Table 2. Two solvents were chosen, 
DMF and pyridine. DMF was chosen for its ability to dissolve a wide range of acids, 
amines and amides. Pyridine was chosen in order to study the efficiency of the 
coupling reaction under basic conditions.  
 













1. Oxyma / DIC 
2. Oxyma / DIC 
DMF 12 h    
Pyridine 12 h    
3. DIC 
4. DIC 
DMF 12 h    
Pyridine 12 h    
5. EDC.HCl 
6. EDC.HCl 
DMF 12 h    
Pyridine 12 h    
7. EDC.HCl/DMAP 
8. EDC.HCl/DMAP 
DMF 12 h    
Pyridine 12 h    
9. TBTU 
10. TBTU 
DMF 12 h    
Pyridine 12 h    
11. NHS/DCC 
12. NHS/DCC 
DMF 12 h    
Pyridine 12 h    
Table 2: Result of screening conditions - reactions monitored by high-performance liquid 
chromatography (HPLC) and mass spectroscopy (MS). 




The combination of Oxyma and DIC showed full conversion to the product in both 
solvents without any sign of by-products (entries 1 and 2 of Table 2). The third and 
fourth entries of the table were the use of DIC without Oxyma. Oxyma is 
traditionally used to prevent racemisation/epimerisation of amino acids, the resulting 
active ester is more stable resulting in less potential side reactions such as the 
formation of N-acylisoureas.
152, 156
 As an achiral acid was used it was natural to try 
the reaction without Oxyma. In both solvents the reaction did not go to completion. 
Although benzylamine was the limiting reagent; it was partially recovered, 
confirming that the reaction did not go to completion.  
The fifth and sixth entries were the use of EDC.HCl. The reaction did not give any 
product and starting materials were recovered. 
For the seventh and eighth entries, catalytic amount of DMAP was used in 
combination of EDC.HCl to facilitate the reaction. The use of the catalyst help the 
reaction as the product was observed in both solvents, but the reaction did not go to 
completion in pyridine and produced an unidentified by-product in DMF. 
In the ninth and tenth entries, O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium 
tetrafluoroborate (TBTU) was the chosen activating agent. The product was observed 
in both solvents, but without pyridine the reaction did not go to completion.  
The eleventh and twelfth entries were the formation of the NHS activated ester using 
hydroxysuccinimide NHS and DCC. In both solvents the product was formed in full 
conversion. 
To conclude this model study, five conditions gave the desired compound in full 
conversion. Those were Oxyma and DIC in DMF or pyridine, TBTU in pyridine and 




NHS/DCC in DMF or pyridine. Conditions that were found to work on the model 
study were then taken forward and attempted on the dendron.  
Three non peptidic dendrons were designed and synthesised (Scheme 16). These are 
different in their spacers: a two carbon spacer an eight carbon chain to decrease steric 
hindrance between the dendron core and the fluorophore and finally a polyethylene 
glycol PEG spacer to alter probe solubility.  





Scheme 16: Non peptidic dendrons. 
 




The synthesis starts with 2-chlorotrityl functionalised polystyrene resin. The spacers 
were used in large excess at a high concentration of 5 M and hence did not require 
monoprotection.
157
 The isocyanate dendron monomer 4 was freshly prepared and 
attached (Scheme 16), with the Dde groups being removed using 4% hydrazine in 
DMF. The resulting free primary amines were acylated using standard conditions, 
acetic anhydride, pyridine and acetic acid in DMF. The desired compounds were 
obtained in satisfactory yields following TFA cleavage (Scheme 16).  
 
 
Scheme 17: Coupling in solution of the fluorophore. 
 




The final step was the coupling in solution of the dye (Scheme 17). Among the few 
successful conditions found with the model study, the combination of Oxyma and 
DIC was chosen. The reactions were carried out in DMF, although the desired 
compounds were obtained, ELSD analysis showed a complex reaction profile 
therefore giving unsatisfactory yields. It was important to obtain a simple reaction 
profile to be able to later construct a more complex probe with peptide sequences. 
For that purpose, the fluorescein activation was investigated as so far it had been 
assumed to work efficiently and the by-products of the activation to not interfere 
with the amide formation. As NHS activation had shown good results in the previous 
model study and the active ester had been reported to be stable under purification,
154
 
it was chosen for activation studies.  
Dye activation study 
5(6)-Carboxyfluorecein and NHS were dissolved in dry THF, and DCC added and 
the reaction stirred for 2 h (Scheme 18). Surprisingly, the reaction did not meet our 
expectations as a complex reaction profile was observed. 
 
 
Scheme 18: NHS activation of 5(6)-carboxyfluorescein. 
 




Looking in the literature, the phenol groups of fluorescein are known to be reactive 
and readily react with active esters.
153
 It was therefore decided to protect the phenol 
groups of carboxyfluorescein before acid activation. The original protecting group 




Scheme 19: Boc protection of 5(6)-carboxyfluorescein. 
 
Entry FAM Boc2O Pyridine Solvent Temp. Microwave Time 
1 1 eq 2.5 eq 3.5 eq THF 60 °C No 1 h, 12 h 
2 1 eq 4 eq cat THF r.t. No 1 h, 12 h 
3 1 eq 4 eq cat MeCN 60 °C Yes 15 min 
4 1 eq 4 eq cat MeCN 60 °C Yes 30 min 
5 1 eq 4 eq cat MeCN 60 °C Yes 1 h 
6 1 eq 4 eq 10 eq MeCN 100 °C Yes 15 min 
Table 3: Reaction conditions for the Boc protection of 5(6)-carboxyfluorescein - All reactions 
were carried out under anhydrous conditions, and all reactions monitored by TLC. 
 
In the first entry of Table 3 NMR analysis of the crude product showed the presence 
of starting material confirmed by MS and TLC, and the presence of various  
by-products.  
In the second entry milder conditions were attempted as it was thought that heat 
could be responsible for the by-product formation. Pyridine was used in a catalytic 




amount, although fewer by-products were formed, NMR spectroscopy showed the 
reaction did not go to completion as starting material was observed and confirmed by 
MS. Entries 3, 4 and 5 were microwaved assisted reactions. THF being a non-polar 
solvent does not respond well to microwave energy and was for that purpose 
replaced by acetonitrile (MeCN),
158
 with the temperature fixed at 60 °C with three 
reaction times, 15 min, 30 min and 1 h. Once again, none of the reactions went to 
completion. A final attempt at this protection was to increase the amount of pyridine 
to ten equivalents, and increase the temperature to 100 °C over a short time of  
15 min. Once again some by-products were formed, and the presence of starting 
material observed. 
The Boc-protection was not investigated further and a new protecting group was 
sought. The acetyl protecting group, is a commonly used protecting group for the 
protection of the phenol groups of carboxyfluorescein.
159
 
Although commercially available the single isomer version of the carboxyfluorescein 
diacetate N-succinimidyl ester (CFDA-SE) has no published synthesis and while a 
few groups have published different protocols for the single isomer separation of 
carboxyfluorescein, no efficient methods have been reported. The synthesis of 
CFDA-SE and single isomer purification was successfully investigated and reported 
in chapter 3 of this thesis.  
 





Scheme 20: Solution coupling of 5-CFDA-SE with amine 32. 
 
Amine 38 was reacted with 5-carboxyfluorescein diacetate N-succinimidyl ester  
(5-CFDA-SE) in the presence of DIPEA in a mixture of MeCN and DMF at a 
concentration of 0.1 M of 5-CFDA-SE. The crude mixture was unexpectedly 
complex, while the strong orange colour appeared upon addition of the base 
suggesting that the protecting groups had been removed. To further investigate the 
stability of the acetyl groups under basic conditions, 5(6)-carboxyfluorescein 
diacetate (5(6)-CFDA) was stirred in DMF with DIPEA over 3 h. Two variables 




were independently investigated in this study, the equivalents of base and the 
quantity of DMF (reported in Table 4 as the concentration of 5(6)-CFDA). 
 
Entry Base 5(6)-CFSE [5(6)-CFSE] Deprotection 
1 3 eq 1 eq 0.1 M Yes 
2 2 eq 1 eq 0.1 M Yes 
3 1 eq 1 eq 0.1 M No 
4 2 eq 1 eq 0.01 M No 
5 1 eq 1 eq 0.01 M No 
Table 4: Deprotection study conditions of 5(6)-CFDA in DIPEA and 
DMF, [5(6)-CFSE] represent the concentration of 5(6)-CFSE.  
 
Table 4 shows that 3 equivalents of the base in high concentration deprotects the 
phenols (entry 1), 2 equivalents of base in concentrated conditions also cause 
deprotection (entry 2) but lower concentrations preserve the protecting groups (entry 
4). Using solely 1 equivalent of base does not deprotect the phenols regardless of the 
concentration chosen (entry 3 and 5).  
Thus, the reaction of coupling in solution of 5-carboxyfluorescein diacetate  
N-succinimidyl ester to the amine 32 was attempted with lower concentration of  
5-CFDA-SE-53 (0.01 M) and two equivalents of base (Scheme 21). 
 





Scheme 21: Solution coupling of 5- or 6-CFDA-SE to 34.  
 




The reaction was complete after 2 h, and purified using semi-preparative HPLC 
(Scheme 21). Two other probes were synthesised using these conditions (Figure 19). 
The reaction of Scheme 21 was repeated on the two other spacer constructs and the 
protecting groups removed using 20% piperidine in DMF to obtain the three target 
compounds (Figure 20). They were purified using semi-preparative HPLC. 
 
 
Figure 20: Structures of purified products. 
 
Although the yields were not as high as desired due to difficult purification, reaction 
monitoring confirmed full conversion to the product. 




Human neutrophil elastase specific probe 
To develop a human neutrophil elastase specific probe a peptide sequence specific to 
NE must be introduced. The designed probe 44 is shown in Figure 21.  
 
 
Figure 21: Target compound. 
  
The synthesis started in the same manner as seen previously (Scheme 16) with linker 
activation and attachment of 1,8-diaminooctane followed by addition of the 
tribranched monomer unit 4, and Dde removal. The first method was to synthesise 
the fully protected peptide as a single a strand followed by attachment onto the 
dendron. The strategy started with the synthesis of the fully protected peptide shown 
Figure 22 which was synthesised using an automatic peptide synthesiser, with a 
polystyrene resin functionalised with a 2-chlorotrityl linker. 
 





Figure 22: Fully protected elastase peptide 45. 
 
The peptide was cleaved using the cleavage cocktail developed by Barlos,
160
 
consisting of a mixture of acetic acid and trifluoroethanol (TFE) in DCM. 
The next stage was to couple the protected peptide on to the dendron loaded resin. 
However, when attempting, to activate the protected peptide, solubility issues were 
encountered. The amount of solvent required for a concentration of 0.1 M or even 
0.01 M was not sufficient to dissolve the peptide. Due to solubility issues, only one 
equivalent of DIC for three equivalents of peptide was used to prevent unwanted side 
reactions. After 2 h, N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) was 
added to reactivate the peptide and the reaction left for another 2 h. EEDQ has the 
advantage of not reacting with amines but rapidly with carboxylic acid.
161
  
After the reaction, the resin was filtered and washed, however, the ninhydrin test 
showed the presence of free amines. Coupling was repeated under the same 
conditions and reactivated with EEDQ, unsuccessfully. To overcome the solubility 
issue, a wide variety of solvent and solvent mixtures (DMSO, NMP, DMF, DCM) 




were tried in order to find the system that would dissolve the peptide in the smallest 
volume. The peptide did not seem to fully solubilise in any reasonable 
concentrations. 
The second approach to obtain the target compound was to build the peptide step 
wise onto the tribranched resin.  
The resin used so far was a preloaded 2-chlorotrityl polystyrene resin with a loading 
value of 1.2-1.6 mmol/g. This rather high loading value was thought to be a 
disadvantage for the construction of a bulky tribranched dendron. A smaller loading 
value would lower the amount of compound on the resin in turn reducing the steric 
hindrance. The next resin chosen was the 2-chlorotrityl functionalised ChemMatrix 
resin. The loading value being lower (0.65 mmol/g) the performance of this resin was 
promising. In the meantime a shortened peptide sequence for the detection of 
neutrophil elastase was discovered in our research group.
117
 The new targeted 
sequence is shown Scheme 22.  
 





Scheme 22: Synthesis overview. 
 
For the synthesis of AB429-49, 1,8-diaminooctane was used at a high concentration  
(5 M), in the presence of a base. The tribranched monomer unit 4 was loaded onto 
the resin and the Dde protecting groups were removed using hydrazine (Scheme 16). 
Then, the peptide was built stepwise using standard Fmoc strategy. The most 
efficient coupling reagents for Arg(Pbf) were found to be  
O-benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate (HBTU) and 
DIPEA, especially for the addition of Arginine onto Arginine, all other amino acids 
were coupled using a combination of Oxyma and DIC. CFDA-SE being an active 
ester did not require any activating reagents and was added onto the peptide in the 
presence of DIPEA.  




Attempted cleavage (with acetic acid and TFE) did not cleave compound 48 from the 
resin. In the original paper, the compound was attached to the linker through an ester 
moiety. Due to the delocalisation of the charge over the two oxygen atoms, the acid 
moiety is a better leaving group than the amine group. Therefore the latter requires 
stronger conditions to be cleaved (Scheme 23).  
 
Scheme 23: Cleavage mechanism of the trityl linker. 
 
Bollhagen developed a new cocktail for the cleavage of fully protected peptides from 
trityl linkers using hexafluoroisopropanol (HFIP) in DCM.
162
 Interestingly this 
cocktail even dissolves hydrophobic peptides unlike the Barlos method, making it a 
better choice. The new cleavage conditions using 30% HFIP in DCM was successful 
and 48 was cleaved (Scheme 22).  
The final step of the synthesis was the attachment of tetraethylcarboxyrhodamine 
(Rho) via activation with Oxyma and DIC in DMF and added to the solution of 
intermediate 48 (Scheme 22). 
 
 




2.3 In vitro studies 
Cell line studies 
To study the dendron core-structure the six probes (C2CFDA-39, C8CFDA-38, 
PegCFDA-40, C8FAM-42, PegFAM-43, PegRho-41) were incubated with two cell 
types, human adenocarcinomic alveolar basal epithelial cells A549 and primary 
human neutrophils and studied using confocal microscopy. The A549 cell line is 
derived from human pulmonary adenocarcinoma and it is the most used alveolar 
epithelial model.
163
 Unlike neutrophils, A549 cells are not lymphocytes and do not 
participate in the ingestion of foreign organisms, making them a control for cellular 
entry study. 
 






Confocal microscopy studies show that none of the six probes (C2CFDA-39, 
C8CFDA-28, PegCFDA-40, C8FAM-42, PegFAM-43, PegRho-41) entered the cells 
after overnight incubation on A549 cells. Figure 23A, B and C show low 
fluorescence intensities for acetylated fluorescein compounds; arrows highlight 
punctual fluorescence signal where fluorescein must have been deacetylated. Figure 
23D, E display high fluorescence intensity for non-acetylated fluorescein probes, as 
Figure 23: Confocal microscopy images of A549 cells 
incubated with probes. A549 were fixed on multiwell 
chambers using poly-D-lysine. Probes were incubated at 
10 µM for 16 h at 37 °C. A. C2CFDA-39, B. C8CFDA-38, 
C. PegCFDA-40, D. C8FAM-42, E. PegFAM-43, F. 
PegRho-41. A-E. Fluorescein emission image (λex = 488 
nm, λem = 512 – 565 nm). F. Rhodamine emission image 
(λex = 543 nm, λem = 565 – 608 nm). Arrows show: 
localised high fluorescence intensities. Scale bars: 20 µm. 
Images are representative of duplicates experiments 










well as Figure 23F where rhodamine probe was incubated. Non cellular penetration 
of the probes was confirmed by Z-stacking 3D experiments. 
Enzyme kinetics studies 
The peptide sequence used in probe AB429-49 was specific to human neutrophil 
elastase, meaning it is cleaved by this enzyme. However, it must be determined 
whether the peptide sequences on the three branched dendron construction can enter 
the active site of the enzyme to be cleaved. Probe AB429-49 is designed to release an 
unquenched fluorescein moiety following cleavage by the enzyme (Figure 15), with 
the resulting fluorescence recorded. Different concentrations of probe were analysed 





































By measuring the fluorescence (RFU) of various concentration of fluorescein [P], a 
standard curve was realised to allow us to convert units of fluorescence into product 
concentrations (Figure 24) (See appendices section). The Michaelis-Menten graph 




From the graph, Km and Vmax (the maximum rate achieved by the system), can be 
determined. The number of molecules of substrate cleaved by each enzyme unit per 
second is the rate constant (or turn over constant) kcat calculated by dividing the Vmax 


























Slope of the initial linear 






A B C 
D 
Figure 24: Method used to convert raw data to Michaelis-Menten parameters. A. Raw 
data of fluorescence unit increase over time, B. standard curve of concentration of 
fluorophore per fluorescence unit, C. concentration of fluorophore released calculated 
from fluorescence units over time, D. calculated initial rates for substrate 
concentrations. Michaelis-Menten parameters kcat and Km calculated from graph D. 





The Km obtained was: 2.8 ± 0.6 µM, with a kcat: 304 ± 16.1 s
-1





. Although the Michaelis-Menten parameters are not reported for 
this specific peptide sequence
117
 the kcat/Km value for the original peptide 







This study confirms that the probe is a substrate for HNE and therefore could be 
taken to the next stage, namely the study of human neutrophils. 
Primary cell studies 
Neutrophils are primary cells and are extracted from human blood. When a blood 
sample is taken a response called hemostatsis occurs, which is based on clot 
Michaelis-Menten curve of AB429













Figure 25: Experimental Michaelis-Menten graph of AB429 incubated with human 
sputum elastase (17 nM). 




formation. The process must be controlled in order to separate the different 













Insoluble fibrin production and platelets activation is initiated by thrombin and is 
produced by the prothrombinase complex in the presence of calcium ion.
165
 By 
removing the presence of calcium ions, the cascade is stopped and the blood sample 
is prevented from clotting. Various anticoagulants can be used such as, oxalate 
(COO)2
2-
, EDTA, or Sodium citrate.
166
 Once the anticoagulant is added, the blood 
sample can be centrifuged to separate the serum and platelets, and red and white 
blood cells (Figure 26A). Serum can be extracted from the platelets by addition of 
calcium chloride, which activates the platelets into a plug, allowing filtration of the 
serum. Dextran and sodium chloride are added to the bottom layer causing 
sedimentation which allows for easy separation of the white blood cells from the red 
blood cells. White blood cells can then be separated using Percoll
TM
, a non-toxic 




Figure 26: Blood preperation - Courtesy of Neil McDonald. A. 
Separation of serum and platelets (top layer) from red and white blood 
cells (dark bottom layer). B. Percoll
TM
 gradient separation, base of the 
top layer contains monocytes, base of the middle layer contains 
neutrophils, and base of the bottom layer contains red cells. 




carefully superposing layers of different concentrations of Percoll
TM
 in PBS we can 
allow the white blood cells to separate, and obtain neutrophils (Figure 26 B). 
In Figure 27 confocal experiments on activated neutrophils showed cellular entry and 
de-acetylation of the three acetylated probes (C2CFDA-39, C8CFDA-38 and 
PegCFDA-40).  
 
C8CFDA-38 showed stronger fluorescence intensities than C2CFDA-39 and 
PegCFDA-40 (Figure 27 A,B and C). The non-acetylated probes and rhodamine 
Figure 27: Confocal microscopy images of activated neutrophils incubated with 
probes. (The neutrophils were purified from human blood sample of healthy 
volunteers courtesy of Dr. Neil McDonald and Miss Emma Schoefield). Neutrophils 
were fixed on coverslip using fibronectin. Probes were incubated at 10 µM for 1 h at 37 
°C, and neutrophils activated by addition of calcium ionophore A23187.
5
 A. C2CFDA-
39, B. C8CFDA-38, C. PegCFDA-40, D. C8FAM-42, E. PegFAM-43, F. PegRho-41. A-
E. Left fluorescein emission image (λex = 488 nm, λem = 512 – 565 nm), right image 
merge of bright field and fluorescent image. F. Left rhodamine emission image (λex = 
543 nm, λem = 565 – 608 nm) right image merge of bright field and fluorescent image. 
Arrows show: localised high fluorescence intensities. Scale bars: 20 µm. Images are 













probe did not seem to enter the cells even upon neutrophil activation. To confirm the 
cellular entry of the acetylated probes, Z-stacking 3D experiments were carried out 




Z-stack 3D experiments of the acetylated probes show fluorescence intensity within 
the cell in all planes confirming the cellular penetration of the compounds. 
Figure 28: Z-staking confocal microscopy images of 
activated neutrophils incubated with probes. (The neutrophils 
were purified from human blood sample of healthy volunteers 
courtesy of Dr. Neil McDonald and Miss Emma Schoefield.) 
Neutrophils were fixed on coverslip using fibronectin. C8CFDA-38 
(10 µM) added, and neutrophils activated by addition of calcium 
ionophore A23187. A-F Show the different planes of a neutrophil 
cell. Fluorescein emission image (λex = 488 nm, λem = 512 – 565 
nm). Slice thickness: 0.44 µm. Scale bars: 5 µm. Images are 
representative of duplicates experiments carried out on different 
days.  
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In Figure 29 the probe shows some cell penetration and, it remains uncleaved in the 
presence of non-activated neutrophils. In Figure 30, calcium ionophore A23187 was 
added and the resulting activation of the neutrophils was recorded. All experiments 











Figure 29: Confocal microscopy images of neutrophils incubated with AB429-
49. (The neutrophils were purified from human blood sample of healthy volunteers 
courtesy of Dr. Neil McDonald and Miss Emma Schoefield). Neutrophils were fixed on 
coverslip using fibronectin, and AB429-49 (10 µM) added. A. Fluorescein emission 
image (λex = 488 nm, λem = 512 – 565 nm), B. rhodamine emission image (λex = 543 
nm, λem = 565 – 608 nm), C. merge of fluorescein and rhodamine emission images. 
Scale bars: 20 µm. Images are representative of duplicates experiments carried out on 
different days. 
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In Figure 30B clusters of strong fluorescence intensities can be seen inside the cells, 
the probe has therefore entered the neutrophils. From the fluorescein channel, strong 
green fluorescent vesicles have appeared resulting from the cleavage of the branches. 
We can see from the overlay channels that some vesicles are red, indicating that the 
probe has entered the cells but not green indicating that either all branches have been 
Figure 30: Confocal microscopy images of activated neutrophils 
incubated with AB429-49. (The neutrophils were purified from 
human blood sample of healthy volunteers courtesy of Dr. Neil 
McDonald and Miss Emma Schoefield). Neutrophils were fixed on 
coverslip using fibronectin, AB429-49 (10 µM) added, and neutrophils 
activated by addition of calcium ionophore A23187. A. Fluorescein 
emission image (λex = 488 nm, λem = 512 – 565 nm), B. rhodamine 
emission image (λex = 543 nm, λem = 565 – 608 nm), C. merge of 
fluorescein and rhodamine emission images, D. merge of bright field 
and fluorescein and rhodamine emission images. Arrows show: 
localised high fluorescence intensities. Scale bars: 20 µm. Images 










cleaved or that none of the branches have been cleaved remaining unquenched. To 
further investigate dye co-localisation, the microscope was set to analyse individual 

























Figure 31 displays a close up image of a neutrophil. We can confirm from the 
fluorescein channel cleavage of the probe. From the rhodamine channel we can 
Figure 31: Single cell analysis confocal microscopy images 
of activated neutrophils incubated with AB429-49. (The 
neutrophils were purified from human blood sample of healthy 
volunteers courtesy of Dr. Neil McDonald and Miss Emma 
Schoefield). Neutrophils were fixed on coverslip using 
fibronectin, AB429-49 added to the cells at  
10 µM, and neutrophils activated by addition of calcium 
ionophore A23187. A. Fluorescein emission image (λex = 488 
nm, λem = 512 – 565 nm), B. rhodamine emission image (λex = 
543 nm, λem = 565 – 608 nm), C. merge of fluorescein and 
rhodamine emission images, D. merge of bright field, 
fluorescein and rhodamine emission images. Scale bars: 5 µm. 
Images are representative of duplicates experiments carried out 
on different days. 
A B 
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observe the accumulation of the probe in vesicles of the cell. In the overlay channels 
the superposition of the green signal and red signal appears as orange. We can see 
red pockets which can result from molecules being fully cleaved with no fluorescein 
moieties left or molecules that have not been cleaved and fluorescein signal 
quenched. 
To confirm the presence within the cell and rule out the possibility of an artifact due 
to an accumulation of the probe on the cell membrane, Z-stack 3D experiments were 
carried out.  
 
 
The Z-staking 3D experiments confirmed that the probe does enter activated 
neutrophils. Picture 1 to 8 are different planes of the cell, the co-localisation of the 
Figure 32: Z-staking confocal microscopy images of activated neutrophils 
incubated with AB429-49. (The neutrophils were purified from human blood sample of 
healthy volunteers courtesy of Dr. Neil McDonald and Miss Emma Schoefield). 
Neutrophils were fixed on coverslip using fibronectin, AB429-49 (10 µM) added, and 
neutrophils activated by addition of calcium ionophore A23187. 1-8 Show the different 
planes of a neutrophil cell. Images show merge of fluorescein emission image (λex = 488 
nm, λem = 512 – 565 nm) and rhodamine emission image (λex = 543 nm, λem = 565 – 608 
nm). Slice thickness: 0.38 µm. Scale bars: 5 µm. Images are representative of duplicates 
experiments carried out on different days. 
1 2 3 4 
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rhodamine and the fluorescein signals appear orange, and are clearly present 
throughout the different planes.  
The probe enters activated neutrophil and is cleaved inside the cell. To control 
whether the cleavage is specific to elastase the following experiments involved the 
use of sivelestat a well-known elastase inhibitor.
168
 The probes were incubated with 
inhibitor and cells and observed by confocal microscopy. The neutrophils were then 
activated with calcium ionophore A23187 (Figure 33).  
 
 
The negative control experiment shown Figure 33, indicates that the probe has 
entered the cells during activation (Figure 33B), and that the probe is not being 
Figure 33: Confocal microscopy images of activated neutrophils in the 
presence of elastase inhibitor Sevelestat and incubated with probe 
AB429-49. (The neutrophils were purified from human blood sample of 
healthy volunteers courtesy of Dr. Neil McDonald and Miss Emma 
Schoefield). Neutrophils were fixed on coverslip using fibronectin, and 
incubated with elastase inhibitor Sevelestat at 50 µM for 15 min at 37 °C. 
AB429-49 was added to the cells at 10 µM in the presence of Sevelestat, 
and neutrophils activated by addition of calcium ionophore A23187. A. 
Fluorescein emission image (λex = 488 nm, λem = 512 – 565 nm), B. 
Rhodamine emission image (λex = 543 nm, λem = 565 – 608 nm). Scale 
bars: 20 µm. Images are representative of duplicates experiments carried 
out on different days. 
A B 








Six non peptidic probes were synthesised with optimisation of reaction conditions. 
Studies on A549 cells show that the dendron core does not enable penetration of the 
cells while acetylation of the fluorescein allows cell penetration of activated 
neutrophils. A dual labelled dendron-based probe specific to neutrophil elastase was 
synthesised. Its cleavage by the target enzyme was confirmed by enzyme kinetics 
studies. This peptidic probe was not cleaved in the presence of non-activated 
neutrophils while after activation of the neutrophils a strong fluorescence increase 
resulted. When a neutrophil elastase inhibitor was used in the presence of activated 
neutrophils the probe was observed to enter the cell but was not cleaved, confirming 
its specificity to NE.  
 
 





Synthesis and in vitro studies of 
single isomers of fluorescein and 
rhodamine derivatives 
 
Part of this chapter was published as: 
Aurélie Brunet, Tashfeen Aslam and Mark Bradley, Separating the isomers – 
Efficient synthesis of the N-hydroxysuccinimide esters of 5 and 6-carboxyfluorescein 
diacetate and 5 and 6-carboxyrhodamine B, in Bioorganic & Medicinal Chemistry 
Letters (2014).  
 
3.1 Introduction  
Fluorescent probes combined with imaging techniques are capable of sensing and 
visualising processes from living cells to pre-clinical and even clinical applications. 
The development of this area of scientific research requires fluorophores with greater 
purity, solubility and ease of conjugation. Amongst the abundant classes of 
fluorophores xanthene derivatives, such as fluorescein and rhodamine dyes, have 
attracted extensive interest due to features such as commercial availability, low cost, 









Figure 34: Xanthene based dyes. 
 
3.1.1 Fluorescein and its derivatives 
Fluorescein was originally synthesised in 1871 by Adolf von Baeyer.
170
 It possesses 
high fluorescent quantum yield (ΦFluorescein: 0.91 ± 0.05 in 1 M NaOH)
171
 and 
represents one of the most popular fluorescent labelling agents of biomolecules.
172, 
173
 Protocols using fluorescein derivatives to label glycoproteins or immunoglobins 
are well established,
172
 and the literature is rich with biomolecules labelled with 























Peptides can be easily tagged with carboxyfluorescein as shown by Nguyen (2001) 
who developed fluorescent probes that label nerves in human tissues, showing a 
contrast with adjacent tissue up to ten fold, potentially facilitating surgical repair of 
injured nerves and help prevent accidental transection.
198
  
Common methods for DNA sequencing, such as the Sanger method, are using 
fluorescein.
199
 Developed in the mid-1970s, the Sanger method uses chain 
terminating fluorescent or radiolabelled nucleotides and is to this date still described 
as the “gold standard of DNA sequencing and mutation identification”.
200
 




Carboxyfluorescein remains at the forefront of fundamental and applied research in 
DNA sequencing as recently shown by Xie (2011) and his new method of DNA 
sequencing using fluorophore releasing nucleotides,
201
 or the SMRT technology 
developed from Pacific biosciences, a technique also based on fluorophore releasing 
nucleotides in conjunction with powerful light microscopes able to detect volumes of 
10
-21
 litres, reaching a read of ten bases per second leading to a chain of thousands of 
nucleotides to be made within minutes.
202
 5(6)-Carboxyfluorescein is rendered  
non-fluorescent by phosphorylation and conjugation to the four nucleoside 
triphosphates. When a DNA polymerase recognises the nucleoside, the 
carboxyfluorescein moiety is released and the resulting fluorescence detected.  
The monitoring of enzymatic activities by fluorescein has also been illustrated by 
Tanaka (2010), who designed a non-fluorescent phosphate-linked fluorescein 
polymer that in the presence of alkaline phosphatase, releases fluorescein.
203
 
Fluorescein has also been derivatised into various chemical sensors to detect 












The synthesis of carboxyfluorescein typically results in a mixture of isomers  










Figure 35: Synthesis of 5(6)-carboxyfluorescein. 
 
Kvach (2007), studied the different properties of 5- and 6-carboxyfluorescein 
attached to an oligonucleotide and although they have similar absorbance profiles 
and fluorescence quantum yields the emission band of 6-carboxyfluorescein was 
substantially sharper making it a better choice than 5-carboxyfluorescein for 





Figure 36: Absorption spectra (left) and fluorescence spectra (right) of 5-carboxyfluorescein 
labelled oligonucleotide 7a (straight lines) and 6-carboxyfluorescein labelled oligonucleotide 
7b (doted and dashed lines) in sodium carbonate buffer, pH 8.35, excitation at λ = 470 nm. 
Reprinted with permission from Kvach.
205









3.1.2 Carboxyfluorescein diacetate N-succinimidyl ester 
The most extensively used derivative of fluorescein is a mixture of  
5(6)-carboxyfluorescein, while another widely used derivative is the diacetate  
N-succinimidyl ester commonly referred to as CFSE or CFDA-SE (Figure 37). 
Confusion over the acronyms is present in the literature when CFSE should only be 
used for carboxyfluorescein N-succinimidyl ester, CFDA for carboxyfluorescein 






















The mode of action of carboxyfluorescein diacetate N-succinimidyl ester is 
hypothesised in Figure 37.
1
 The two acetate side chains render the molecule highly 















membrane permeable. Once inside cells, the N-succinimidyl ester reacts with 
proteins and the acetate groups are removed by intracellular esterases. The resulting 
fluorescent proteins cannot exit the cells, allowing thorough washes to remove any 
unreacted dye that could have led to high background fluorescence, a considerable 
advantage in flow cytometry and fluorescent microscopy.
1
 Due to its effective 
coupling to intracellular amines and its long-lived fluorescence, it is widely used to 
track cellular division-dependent processes.
1, 206-210
  
To highlight its wide-spread application, 5(6)-carboxyfluorescein diacetate  
N-succinimidyl ester has been reported 160 times in Nature journals and 18 times in 
Science journals in 2013 alone. However, it is used predominantly as a mixture of 
isomers and is also very expensive.  
 
3.1.3 Carboxytetraethylrhodamine N-succinimidyl ester 
Rhodamine and derivatives such a tetraethylrhodamine (Rhodamine B) and 
tetramethylrhodamine (TAMRA) were discovered by Noelting and Dziewonsky in 
1905.
211
 They are readily available, inexpensive, nontoxic, are highly water soluble 





 The fluorescence of rhodamine is photo and chemically stable
169
 and, 
its excitation and emission wavelengths (500 - 600 nm) are within the range where 
autofluorescence of the cells is negligible.
94, 213
 These points explain why rhodamine 
dyes remain, over a hundred years later, extensively used for applications such as 
fluorescence standards for quantum yields,
214
 detection of reactive oxygen species,
94
 






















 and protein labelling.
169, 235-238
  
Tetraethylrhodamine, also called rhodamine B, basic violet 10 and is sometimes 
wrongly referred to as TAMRA.
233
 Despite these extended uses, the activation of 
rhodamine B to the N-hydroxysuccinimide (NHS) ester is not well established. 
 
3.1.4 Chapter aim 
 
 
Figure 38: N-succinimidyl esters of Rhodamine 
 
In this chapter, the separation of isomers of the 5- and 6- carboxyfluorescein 
diacetate N-succinimidyl esters (CFDA-SE) and 5- and 6- carboxytetraethyl 
rhodamine N-succinimidyl esters were investigated. Additionally, a study of  
5-Rho-SE and 6-Rho-SE as “red” alternatives of carboxyfluorescein diacetate  
N-succinimidyl ester for proliferation studies of CD4
+
 T lymphocytes and the cellular 
labelling differences between the isomers were explored.  
 
 




3.2 Results and discussion 
3.2.1 Synthesis of single isomers 
Carboxyfluorescein diaceate N-succinimidyl ester 
In this thesis a simple two-step process is reported for the synthesis and subsequent 
separation of the two isomers of diacetate of 5- and 6- carboxyfluorescein  
N-hydroxysuccinimide esters. The proposed route, unlike previously reported 
methods,
204
 has the advantage to offer easy separation of the two isomers using a 
small plug of silica.  
 
 
Scheme 24: Acetylation of phenol groups of carboxyfluorescein. 
 
Initially, the procedure reported by Tour (2007) was attempted,
159
 stirring  
5(6)-carboxyfluorescein in pyridine with acetic anhydride (Ac2O) and acetic acid for 
3 h at 60 °C. The yields were extremely scale dependant and the method was not 
optimal. Thus the reaction was carried out at 100 °C and the removal of acetic acid as 
a solvent shortened the reaction time to 30 min, probably due to the increased 
concentration of acetic anhydride. Pyridine was as expected crucial for the reaction, 
and its removal prevented the formation of the product.  
The purification reported was via trituration,
159
 but a mild acid wash proved to be an 
easier, more reliable method to purify the product. This newly improved procedure 




gave consistent yields (over 95%) on scales ranging from 200 milligrams to  
15 grams. 
 
Scheme 25: NHS activation and isomer separation of 5- and 6- CFDA. 
 
In the literature numerous conditions have been reported to give NHS esters.
154, 239
 A 
study was carried out at room temperature to determine optimal conditions (Table 5), 
with 5(6)-diacetatecarboxyfluorescein the limiting reagent. The desired compound 
was formed in all cases, but, only a few conditions gave full conversion (Table 5). 
Entry 1 was carried out under dry conditions to assess whether or not the presence of 
water affected the reaction. The HPLC profile of reactions 1 and 2 was identical 
suggesting that the presence of water did not affect the reaction, while also indicating 
the presence of starting material. In entry 3 DMAP was added along with NHS and 
DCC, but full conversion was again not obtained. The replacement of THF by DCM 
in entry 4 allowed the reaction to reach completion in 1 h. Entries 5, 6 and 7 showed 




the combination of NHS and EDC.HCl in DCM or DMF did not reach completion. 
Nevertheless, the use of NHS with DIC (Entry 7) in DCM gave full conversion 
within 30 min. The reaction was successfully repeated on scale ranging from 100 
milligrams to 10 grams. 
 
Entry Activating Agents Solvents Time Full conversion 
1 NHS, DCC Dry THF 2 h No 
2 NHS, DCC THF 2 h No 
3 NHS, DCC, DMAP THF 2 h No 
4 NHS, DCC DCM 1 h Yes 
5 NHS, EDC.HCl DCM 2 h No 
6 NHS. EDC.HCl DMF 2 h No 
7 NHS, DIC DCM 30 min Yes 
 
Table 5: Study of NHS activation of 5(6)-diacetatecarboxyfluorescein (1 eq, 0.1 M) with 
indicated reagents (1.2 eq) at room temperature. Conversion monitored by HPLC, TLC 
and MS. 
 
Unlike 5(6)-carboxyfluorescein, the isomers of 5(6)-carboxyfluorescein diacetate  
N-succinimidyl ester (CFSE) are easily separable by simple column chromatography. 
Indeed, the retention factors (Rf) are 0.37 and 0.53 for 5-CFSE-53 and 6-CFSE-54 
respectively (in 50% ethylacetate in toluene), while the isomers of  
5(6)-carboxyfluorescein co-run in all attempted solvent combinations. Using a slow 
gradient from 100% toluene to 10% EtOAc in toluene using column 
chromatography, yields as high as 41% and 42% for 5- and 6-CFDA-SE respectively 




were obtained. For larger scales, the isomers were separated on a silica plug (15 g 
scale 35% and 25%, for 5- and 6-CFDA-SE respectively).  
The entire two-step procedure takes 1 day, and once purified and dried, CFDA-SE 
can be kept at room temperature for over 4 months without degradation.  
Carboxy tetraethyl rhodamine N-succinimidyl ester 
The separation of the isomers of 5(6)-carboxytetraetheylrhodamine and  
5(6)-carboxyrhodamine B was straight-forward using a gradient of 
TEA:DCM:MeOH (5:95:0 to 5:75:20).  
To form the N-succinimidyl active ester of carboxyrhodamine B, various conditions 
were attempted and were summarised in Table 6. Initially the combination of NHS 
and DIC used for the activation of carboxyfluorescein was attempted, however the 
presence of a by-product was observed (Table 6 – Entry 1). THF was replaced with 
dry DCM to optimise the solubility of all reagents and although the starting material 
disappeared, the by-product remained (Entry 2). DIC was replaced with EDC.HCl 
and the equivalents reduced to 1.05 instead of the previous 1.5 equivalents. The 
reaction was also attempted in dry THF but after 1 h the by-product was also present. 
The reagents quantities were increased to 1.5 equivalents and the solvent changed to 
dry acetonitrile (MeCN). After 2 h the by-product still remained. Mass spectrometry 
showed the by-product was the di-activated compound 55 (Figure 39), benzylamine 
was added to the reaction and the di-benzylated compound 56 was isolated  
(Figure 39). 
 






To regioselectivity obtain a reaction of the 5- or 6-carboxylic acid over the  
3-carboxylic acid, the rhodamine must react in its closed form. Unlike fluorescein, 
rhodamine B is closed under basic conditions and open under acidic conditions.
240
 
Caminade showed that when the 3-carboxylic acid was converted to an active ester 
and reacted with an amine the resulting amide forms the closed form of the 
rhodamine (spirolactam) rendering the molecule non fluorescent.
219, 221, 222, 224, 226, 241
 
It was therefore crucial to prevent the 3-carboxylic acid from reacting, by increasing 
the pH with the addition of a base. Although by-product formation was successfully 
prevented, very low conversion rates were observed (Entry 5-11). Longer reaction 
times reaching 12 h and higher temperatures (up to 120 °C) were attempted, but the 
conversion rate did not improve and extreme conditions yielded the hydrolysis of the 
product to the original starting material (Entry 5-11). Increasing to 1.5 equivalents 
NHS and EDC.HCl instead of 1.05 did not improve the reaction (Entry 12). 
Decreasing the amount of base from 9 equivalents to 2 equivalents and lowering the 
temperature to 0 °C resulted in the formation of the by-product (Entry 11).  
A patent reported the successful synthesis of carboxytetraethylrhodamine  
N-succinimidyl ester using DSC, and DMAP.
242
 These reaction conditions were used 
Figure 39: Di-activated by-product and the di benzylated product. 




but as expected the lack of base gave the formation of the by-product (Entry 21). 
TEA was therefore introduced into the reaction and quantities of DSC and DMAP 
were varied (Entry 15-20). To prevent by-product formation 9 equivalents of base 
were used with 2 equivalents of DSC (Entry 18-20). Full conversion was obtained in 
1 h with an increase of DMAP to 5 equivalents (Entry 20).  
 
Although full conversion was obtained the purification proved difficult, as solvent 
removal caused hydrolysis of the product. To ease purification, the organic base was 
replaced with sodium carbonate (Entry 22) and potassium carbonate (Entry 23). 
However, both gave by-products. The conditions yielding to full conversion found in 
Entry 20 using DMAP, DSC and TEA were used but the solvent replaced by DCM 
for its low boiling point (Entry 24-26), to obtain the optimum conditions (Entry 26).  
 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The optimal route was therefore to separate the isomers via column chromatography 
under basic conditions. These were converted to their corresponding N-succinimidyl 
ester using a combination of DSC, DMAP and TEA. The reaction was then quenched 
with 10 equivalents of acetic acid to prevent rearrangement and decomposition of the 
Scheme 26: 5- and 6- carboxyrhodamine B ester synthesis. 




active ester (when concentrated). The mixture was purified using column 
chromatography eluting with 1% AcOH in acetone.  
 
3.2.2 Cell proliferation assay on primary T cells 
Immune system  
When a foreign entity succeeds in overcoming the human body’s physical barriers 
(skin, mucous membranes, saliva proteases), an immediate line of defence called the 
innate immune system is activated. This first, non-specific response will react to 
destroy or contain this invading organism (as well as any contaminated cells).
125
 A 
broad range of pathogens can be recognised by the innate immune system. However, 
the diversity of this defence is limited and has no memory of encountered pathogens. 
Thus, the response remains the same even under repeated exposure to a pathogen. If 
the spreading of the pathogen persists, a second line of defence called adaptive 
immune system will develop. This response predominately involves two types of 
cells called T lymphocytes and B lymphocytes (Figure 40). These cells possess an 
almost infinite number of extremely diverse and adaptive receptors that will 
specifically target foreign entities or antigens.
243
 Pathogens are remembered by 
memory cells and the defence will be more vigorous and more finely tuned with 














Non activated T cells also called naïve T cells, have a long lifespan, they rarely 
divide, circulate in blood and lymph and populate certain areas of the body such as 
the spleen.
244
 Binding of a target cell by T cells activates them to proliferate 
rapidly.
245
 T cell receptors do not bind to antigens that are soluble or in their native 
conformation. In order for a T cell to respond to an antigen, a separate host cell must 
first digest it into peptide fragments, and then attach the individual peptides to 
specialized cell surface molecules called major histocompatibility complex (MHC) 
molecules. It is the overall shape of the peptide–MHC complex, presented as a unit 
by the host cell to the T cell, that is critical for recognition by the T cell receptor.
246
 
T cells can be divided into two categories: CD8
+
 T cells and CD4
+
 T cells. CD8
+
 T 
cells are defined by the presence of CD8 receptors on the cell membrane. They act as 
killer or cytotoxic cells. They specifically recognise and lyse altered host cells such 




 T cells present CD4 receptors 




































on the cell membrane. They are also called T helper cells as they produce signalling 
molecules called lymphokines to assist B cells in their antibody production and CD8
+
 




 T helper cells (Th) can 
synthesise a variety of lymphokines immediately after activation but differences in 
their release pattern can further divide them into subtypes.
247
  
T cells extraction from spleen 
T cells were chosen as they were the first population studied by Parish et al. when 
they initially identified CFDA-SE as a tracking dye for cell migration.
1, 248
 
Furthermore, CFDA-SE use for measuring lymphocyte proliferation by flow 
cytometry has become a widely used and well established assay.
1, 249
 Splenocytes 
from three C57BL/6 mice were used to isolate T lymphocytes. C57BL/6 mice are a 
wild type mouse strain containing a full complement of murine genes (no genetic 
modification).  
Spleens were extracted from the three mice and T cells separated (in collaboration 
with Dr. Chesney Michels and Miss Emma Scholefield). The T cell population was 
purified by magnetic separation using MicroBeads and an autoMACS pro 1400 
(Miltenyi Biotec).  
The labelling of the cells was carried out according to standard protocol that can be 





 Probes were individually incubated for 10 min at 37 °C. 
The reaction was stopped by the addition of cold complete media, which contains 
proteins
251
 that quench unreacted active esters. The cells were thoroughly washed to 
ensure complete excess probe removal. Each cell experiment was re-suspended in 




complete media, halved and plated onto a 96-well plate pre-coated with anti-CD3/28 
to activate cell division.
252
 The cells were incubated at 37 °C for 48 h and 72 h before 
flow cytometry experiments and microscopy.  
Microscopy studies 
 
Figure 41: Microscopy images of primary T cell clusters. T cell labelled with 6-Rho-SE-
51 activated with anti-CD3/28 and cultured for 3 days at 37 °C. A. Rhodamine emission 
image (λex = 543 nm, λem = 565 – 608 nm). B. Bright field image. Scale bar equals 200 µm. 
Arrows highlight some cell clusters. 
 
After labelling with probes (5-CFDA-SE-53, 6-CFDA-SE-54, 5-Rho-SE-50 and 6-
Rho-SE-51) the cells were cultured for 72 h and from microscopy studies, cellular 
division was assessed, with observation of cell clusters. Figure 41A and B show T 
cells where 6-Rho-SE-51 has been used and analysed under rhodamine emission 
chanel and bright field.  
Flow cytometry studies 
After labeling with probes (commercial 5(6)-CFDA-SE, 5-CFDA-SE-53, 6-CFDA-
SE-54, 5-Rho-SE-50 and 6-Rho-SE-51), the cells were left to divide at 37 °C, and 
analysed using flow cytometry after 72 h and 96 h. Flow cytometry allows the 
B A 




measurement of fluorescence intensity in individual cells, cells that have been 




High fluorescence intensities from the cells incubated with 5-CFDA-SE-53 and  
6-CFDA-SE-54 confirmed that the cells had been succesfully labelled (Figure 42). 
Higher fluorescence intensities were seen in cells labelled with 5-CFDA-SE-53 
compared to cells labelled with 6-CFDA-SE-54. Decrease in fluorescence intensity 
over time due to cellular division was expected, however, it was not observed.  
Figure 42: Fluorescence histograms of T cells labelled with 5-CFDA-SE-53 (5 µM) (dark 
blue) and 6-CFDA-SE-54 (5 µM) (turquoise) after 72 h (solid lines) and 96 h (dotted lines). 




5-CFDA-SE-53 5 µM 72 h 
5-CFDA-SE-53 5 µM 96 h 
6-CFDA-SE-53 5 µM 72 h 
6-CFDA-SE-53 5 µM 96 h 
Unlabelled cells 
 






Fluorescence was observed from cells incubated with 5-Rho-SE-50 and 6-Rho-SE-
51, confirming successful labeling (Figure 43). Stronger fluorescence intensities 
were observed for cells labelled with 5-Rho-SE-50 than with cells labelled with 6-
Rho-SE-51 (Figure 43).  
The fluorescence intensity of cells labelled with 5-CFDA-SE-53 and 6-CFDA-SE-54 
cannot be compared to those labelled with 5-Rho-SE-50 and 6-Rho-SE-51. The BD 
Canto II FACS machine used has an excitation source with three lasers at the 
wavelengths of 405 nm, 488 nm and 633 nm. Therefore rhodamine based compounds 
are excited at 488 nm (Figure 44).  
Figure 43: Fluorescence histograms of T cells labelled with 6-Rho-SE-51  
(5 µM) (purple) and 5-Rho-SE-50 (5 µM) (pink) after 72 h (solid lines) and 96 h (dotted 




6-Rho-SE-51 5 µM 72 h 
6-Rho-SE-51 5 µM 96 h 
5-Rho-SE-50 5 µM 72 h 
5-Rho-SE-50 5 µM 96 h 
Unlabelled cells 
 









The above diagram shows the laser excitation of the machine (488 nm) as well as the 
two selected emission filters fluorescein (515 - 545 nm) and rhodamine (574 - 606 
nm). From the diagram it is clear that the excitation wavelength is ideal for 
fluorescein but too low for optimum rhodamine excitation.  
 
3.2.3 Cell proliferation assay on jurkat cell line 
Flow cytometry studies 
To further investigate these compounds, proliferation experiments were repeated on 
Jurkat cells. Jurkat cells are human leukaemic T cells, developed in the early eighties 
as a source of human T cells.
254-256
 The cells were incubated with five probes: 
commercial 5(6)-CFDA-SE, and the four synthesised single isomers 5-CFDA-SE-53,  
6-CFDA-SE-54, 5-Rho-SE-50 and 6-Rho-SE-51, at the concentraions of 5 µM and 1 
µM for 10 min at 37 °C.
250























cells washed thoughroughly to ensure excess probe removal. The cells were analysed 
by flow cytometry over six days. 





Figure 45: Fluorescence histograms of Jurkat cells labelled with A. 5-CFDA-SE (1 µM) 
over 6 days, B. 6-CFDA-SE (1 µM) over 6 days, C.  5(6)-CFDA-SE (5 µM), 5-CFDA-SE 
(1 µM) and 6-CFDA-SE (1 µM) at day 0 and day 6. FITC-A channel (λex = 488 nm,  




6-CFDA-SE 1 µM Day 0 
6-CFDA-SE 1 µM Day 2  
6-CFDA-SE 1 µM Day 3 
6-CFDA-SE 1 µM Day 6 
Unlabelled Cells 
 
5-CFDA-SE 1 µM Day 0 
5-CFDA-SE 1 µM Day 2  
5-CFDA-SE 1 µM Day 3 





5(6)-CFDA-SE 5 µM Day 0 
5(6)-CFDA-SE 5 µM Day 6 
5-CFDA-SE 1 µM Day 0 
5-CFDA-SE 1 µM Day 6 
6-CFDA-SE 1 µM Day 0 




Day 0 Day 2 Day 3 Day 6 Day 0 Day 2 Day 3 Day 6 
Day 0 Day 6 




At t = 0, the fluorescence intensities of the cells incubated with 5-CFDA-SE-53 and  
6-CFDA-SE-54 at a concentration of 5 µM were off scale, while fluorescence 
intensity of cells incubated at 1 µM was within the scale and is shown Figure 45A 
and Figure 45B. Decrease in fluorescence intensity over time was observed for 
population labelled with 5-CFDA-SE-53 and 6-CFDA-SE-54, confirming division of 
the cells. 
Fluorescence intensity was higher in cells labelled with 5-CFDA-SE-53 than in cells 
labelled with 6-CFDA-SE-54, resulting in 5-CFDA-SE-53 labelled population to be 
traced on the 6
th









Fluorescence intensity observed by flow cytometry in Jurkat cells incubated with  
5-Rho-SE-50 and 6-Rho-SE-51 confirmed cellular labeling property of the probes. 
Decrease in fluorescence intensity over the 6 days was observed for both 6-Rho-SE-
51 labelled cells (Figure 46A) and 5-Rho-SE-50 labelled cells (Figure 46B), 
indicating that the fluorophore was passed onto to daughter cell during cell division. 
Figure 46: Fluorescence histograms of Jurkat cells labelled with  
A. 6-Rho-SE-51 (5 µM), B. 5-Rho-SE-50 (5 µM), and analysed over 6 days. PE-A 









6-Rho-SE-51 5 µM Day 0 
6-Rho-SE-51 5 µM Day 2 
6-Rho-SE-51 5 µM Day 3 






5-Rho-SE-50 5 µM Day 0 
5-Rho-SE-50 5 µM Day 2 
5-Rho-SE-50 5 µM Day 3 
5-Rho-SE-50 5 µM Day 6 
Unlabelled cells 
 




The fluorescence intensity of 5-Rho-SE-50 labelled cells was higher than 6-Rho-SE-
51 labelled cells, allowing the 5-Rho-SE-50 labelled population to be tracable over 
the 6 days.  
 
3.3 Conclusions 
5-CFDA-SE-53 and 6-CFDA-SE-54 were successfully synthesised and separated in a 
simple two step procedure. A method for generating the single isomers 5-Rho-SE-50 
and 6-Rho-SE-51 has also been established. The cellular labelling properties of the 
four isomers were compared on primary T cells and on the Jurkat cell line. In both 
experiments the 5-CFDA-SE-53 labelled cells showed stronger fluorescent 
intensities than 6-CFDA-SE-54 labbelled cells.  
5-Rho-SE-50 and 6-Rho-SE-51 labelled T cells and Jurkat cells, and were passed 
onto daughter cell in a similar fashion to CFDA-SE. For both cell types, 5-Rho-SE-
50 labelled population was more fluorescent than 6-Rho-SE-51 labelled population.  
These preliminary results suggest that 5-CFDA-SE-53 is a better reagent for cell 
proliferation assays than 6-CFDA-SE-54, and that 5-Rho-SE-50 can be used for cell 
division assays when a red dye is more convenient. Further investigations, will 
include the study of labelled T lymphocyte cultured in vivo, and the investigation of 
the labelling properties of the probes on different cell types. 
 





Nuclear localisation dual-labelled 
dendron probes 
4.1 Introduction  
4.1.1 Delivery to the nucleus 
The nucleus is a subcellular organelle found in eukaryotic cells. It contains genetic 
material and hosts DNA and RNA synthesis.
257
 Bound by a double membrane, entry 
into and exit out of the nucleus is finely controlled.  
Transport of specific cargos across the nuclear envelope is critical for cell division 
and all cellular processes.
258-260
 Small molecules simply diffuse through nuclear pore 
complexes (NPCs)
261
 which penetrate the double lipid bilayer,
262
 while larger 
molecules such as proteins and DNA must be recognized by specific nuclear 
localisation sequences (NLSs) to be transported into the nucleus.
263, 264
 The first NLS 
discovered was the seven-mer PKKKRKV found in the SV40 Large T-antigen.
265
 
The mechanism of action of nuclear uptake is illustrated Figure 47. 





Figure 47: Classical nuclear import mechanism, 
where Ran GTP is a binding nuclear protein, Nup2 a 
nuclear pore complex protein and Cse1 an exportin 
protein. Reprinted with permission from Lange.
264
 
Copyright 2007 by the American Society for 
Biochemistry and Molecular Biology. 
In the cytoplasm, the NLS attached to the desired cargo is recognised by the importin 
α-protein. Importin α recognizes the importin β protein which allows transport 
through the nuclear pore.
266
 Once inside the nucleus, the nuclear protein RanGTP 
binds to the complex which causes a conformational change in importin β, resulting 
in the release of importin α. The dissociation of importin α from the cargo is then 
mediated by a nuclear pore complex protein (Nup2) and an exportin protein 
(Cse1).
267
 Finally, importin α is recycled back to the cytoplasm by the exportin 









4.1.2 Nuclear delivery applications 
With the analysis of the human genome sequence, and detailed genetic analysis, 
many disorders have been shown to be the result of genetic mutations.
269
 Gene 
therapy strategies are therefore being investigated for the permanent treatment of 
genetic disorders.
270
 With more FDA approvals of gene therapy treatments such as 
fomivirsen and glybera, increased interest to the field is to be expected.
271, 272
 
One approach to gene therapy is the delivery of DNA or cargo to the nucleus of the 
cells. Using modified viruses allows easy nuclear transport but has raised safety 
concerns.
273
 Thus, non-viral delivery methods have been the subject of considerable 
research over the recent years,
274, 275
 however, the nuclear transport of the 




4.1.3 Impact of fluorophores in nuclear transport 
Puckett et al. (2009) have recently studied the impact of fluorescein on the nuclear 
delivery properties of their probes. Comparison of three peptide complexes of Ru(II):  
Ru-octaarginine (Ru-D-R8), Ruoctaarginine-fluorescein (Ru-D-R8-fluor), and  
Ru-fluorescein (Ru-fluor), showed that fluorescein re-directs the complex into the 
nucleus (Figure 48).  





Figure 48: HeLa cells incubated with 5 μM Ru−D-R8 for 30 min 
(top), 5 μM Ru−D-R8−fluor for 30 min (middle), or 20 μM 
Ru−fluor for 41 h (bottom) at 37 °C in complete medium and then 
imaged by confocal microscopy. Structures of conjugates are 
shown on the left. Reprinted with permission from Puckett.
63
 
Copyright 2009 American Chemical Society. 
 
HeLa cells incubated with Ru D-R8 showed punctate luminescence in the cytoplasm, 
with complete exclusion from the nucleus (Figure 48, top). When fluorescein was 
attached to the ruthenium complex in the presence of octaarginine, the nucleus was 
fluorescently labelled (Figure 48, middle). Finally, the ruthenium complex attached 
to fluorescein without octaarginine shows weak cytoplasmic staining. This ability of 
fluorescein to facilitate delivery to the nucleus was, according to Puckett, partly due 
to its high lipophilicity, increasing the interaction with cell membranes, promoting 








4.1.4 Chapter aim 
Recent studies have identified several proteins that contain more than one NLS, e.g. 
5-lipoxygenase,
276
 herpes simplex virus gene product ICP22,
277
 HIV preintegration 
complex,
278
 papillomavirus oncoprotein E6,
279
 and BRCA2 tumour suppressor gene 
encoded protein.
280
 Multiple NLSs could generate redundancy in proteins that require 




Based on this concept, the aim of this chapter was to synthesise dendron structures 
bearing three NLS sequences with either one or three fluorescein moieties (Figure 
49) as well as the single NLS sequences fluorescently labelled as a comparison. In 
vitro assays would then be carried out to assess whether the structure could penetrate 



















Figure 49: Generic structures of targeted probes. 
NLS Fluorescein NLS Fluorescein 
NLS Probe 3 
NLS Probe 1 NLS Probe 2 
NLS Probe 4 




4.2 Synthesis of dual labelled dendrons 
 
Scheme 27: Synthesis of NLS Probe 1-60. 
 
The synthesis started with aminomethyl ChemMatrix resin, a PEG-based resin 
(loading value 1 mmol.g
-1
, particle size 35-100 mesh). N-Fmoc-Rink linker acid was 
coupled onto the resin using Oxyma and DIC in DMF. The Fmoc group was 
removed using piperidine. The peptide was built using standard Fmoc chemistry; all 
Fmoc protected amino acids were coupled using Oxyma and DIC in DMF except 
Arginine which was coupled using HBTU and DIPEA. After each amino acid 
coupling, the Fmoc was removed using piperidine. 5-Carboxyfluorescein diacetate 




N-succinimidyl ester was added in the presence of DIPEA, and the acetyl groups 
were removed using piperidine. All reactions were monitored using the qualitative 
Kaiser test.
150
 The compound was cleaved from the resin using TFA and purified 
using semi-preparative HPLC (Scheme 27). 
For the next target compound, the dye was attached to the C- terminus of the NLS 
peptide and for this purpose, synthesis started with 2-chlorotrityl linker on a 
ChemMatrix resin (Scheme 28). 





Scheme 28: Synthesis of NLS probe 2-62. 
 




The 2-chlorotrityl ChemMatrix resin (loading value 0.65 mmol.g
-1
, particle size  
35-100 mesh) was pre-activated using thionyl chloride, and the peptide was built 
using standard Fmoc chemistry. After the final Fmoc removal the resulting amine 
moiety was acylated using acetic anhydride. The fully protected probe was cleaved 
from the resin using 30% HFIP in DCM. Volatile solvents were removed under 
reduced pressure in the presence of hexane to prevent concentration of HFIP. The 
acid moiety of the peptide was activated using Oxyma and DIC in DMF and coupled 
to 5-aminofluorescein in the presence TEA. All protecting groups were then removed 
using TFA and purified using semi-preparative HPLC.  
The next targets were tri-branched probes. The first synthesised possessed three 
fluorescein moieties at the N- terminus of the peptide (Scheme 29). 





Scheme 29: Synthesis of NLS probe 3-65. 
 
The synthesis started with aminomethyl ChemMatrix resin. N-Fmoc-Rink linker acid 
was coupled to the resin using Oxyma and DIC in DMF. Fmoc was removed using 
20% piperidine in DMF. N-Fmoc-8-aminooctanoic acid was coupled to the resin 
using Oxyma and DIC in DMF. This additional spacer was chosen to allow fair 




comparison with the NLS probe 4- (Scheme 30). The isocyanate dendron 4 was 
freshly synthesised as shown in chapter 2 and coupled using DMAP and DIPEA. 
Dde groups were removed using a solution of 4% hydrazine in DMF. The peptides 
were built using standard Fmoc chemistry. After final Fmoc removal,  
5-carboxyfluorescein diacetate N-succinimidyl ester was added onto the resin in the 
presence of DIPEA. The desired compound was obtained using semi-preparative 
HPLC after TFA cleavage. 
The next target compound was designed with only one fluorescein moiety at the 
dendron side of the molecule (Scheme 30). 















The synthesis started with the pre-activation of 2-chlorotrytil ChemMatrix resin 
using thionylchloride. Diaminooctane then was attached onto the resin in the 
presence of DIPEA. The use of this spacer will result in a primary amine after 
cleavage from the resin, a handle for the fluorescein attachment. The isocyanate 
dendron was freshly synthesised and coupled onto the resin using DMAP and 
DIPEA. Dde groups were removed using 4% hydrazine in DMF. The peptide was 
built using standard Fmoc chemistry. After the last Fmoc removal the resulting 
amine moiety was acylated using acetic anhydride. The fully protected tri-peptide 
compound was cleaved off the resin under mild conditions using HFIP. The resulting 
compound was coupled to 5-carboxyfluorescien diacetate N-succinimidyl ester in the 
presence of DIPEA. After TFA treatment and semi-preparative HPLC purification 
the NLS probe 4-67 was obtained. 
 
4.3 In vitro studies 
To A549 cells fixed onto poly-D-lysine-coated multi-well chambers, a solution of  
10 µM of the probe of interest in complete DMEM media was incubated at 37 °C for 
1 h. For each probe, two separate experiments were carried out, with or without Syto 
82 orange fluorescent nucleic acid stain (5 µM for 20 min). The media was then 
removed and replaced with fresh media, followed by imaging using confocal 
microscopy using excitation wavelengths of 488 nm (fluorescein) and 543 nm (Syto 
82).  






In Figure 50 we see A549 cells incubated with fluorescein labelled single stranded 
NLSs. The fluorescence intensity is only observed outside the cells and therefore did 
not penetrate the cell membrane. NLS Probes 1-60 and 2-62 did not show any 
nuclear labelling, or cytoplasmic labelling. The NLS sequence combined with one 
fluorescein moiety did not penetrate the cell membrane of A549 cells, thus, the 







Figure 50 Confocal microscopy images: A549 fixed on poly-D-lysine-
coated multi-well chamber, incubated with probe for 1.5 h. A. NLS probe 1-
60 (10 µM), B. NLS probe 2-62 (10 µM), for 1 h. Fluorescein emission image 
(λex = 488 nm, λem = 501 – 522 nm). Scale bars 20 µm. Images are 























The fluorescein labelled tri branched NLS dendron 67, incubated in A549 cells is 
shown in Figure 51. From figure A and B we can observe fluorescence within the 
cells. The fluorescence is punctually distributed throughout the cytoplasm which 
implies endocytosis and is consistent with previous work.
63, 281
 In image 2, the nuclei 
are stained red and complete nuclear exclusion of the probe is clear. Entrapment in 





Figure 51 Confocal microscopy images: A549 fixed on poly-D-lysine-
coated multi-well chamber, incubated with NLS probe 4-67 (10 µM) 
(structure above images) for 1.5 h at 37 °C. A. Fluorescein emission image 
(λex = 488 nm, λem = 512 – 565 nm), B. nuclei stained red with Syto 82, 
merge of fluorescein emission wavelength and stain emission wavelength 
(λex = 543 nm, λem = 576 – 619 nm). Arrows highlight high fluorescence 
intensities. Scale bars 20 µm. Images are representative of duplicates 





Fluorescein NLS Probe 4-67 









Remarkably, the triple fluorescein labelled dendron NLS probe 3-65 enters the 
nucleus under the same incubation conditions for which the NLS probe 4-67 is 
excluded (Figure 51 and Figure 52). NLS probe 3-65 shows diffuse cytoplasmic and 
nuclear fluorescence, strong nuclear staining, and some punctate cytoplasmic 
staining. To further confirm the presence of the probe within the nucleus further 
confocal microscopy experiments were carried out (Figure 53). 
 
Figure 52 Confocal microscopy images: A549 fixed on poly-D-lysine-coated multi-well 
chamber, incubated with NLS probe 3-65 (10 µM) (structure above images) for 1.5 h. A. 
Nuclei stained red with Syto 82, merge image of fluorescein emission image (λex = 488 nm, 
λem = 512 – 565 nm) and stain emission image (λex = 543 nm, λem = 576 – 619 nm), B. nuclei 
stained with Syto 82, fluorescein emission image, C. nuclei unstained, fluorescein emission 
image. Images are representative of duplicates experiments carried out on different days. 
Scale bars 20 µm. 





Fluorescein NLS Probe 3-65 





Figure 53: Confocal microscopy images: A549 fixed on poly-D-lysine-coated multi well 
chamber, incubated with NLS probe 3-65 (10 µm) for 1.5 h. Nuclei stained red with Syto 
82. A-E. Show the different planes of a neutrophil cell. F, G and H. Show slice 15/30, at 
different wavelengths. A-E, H. Merge of fluorescein emission images (λex = 488 nm, λem = 
512 – 565 nm), and stain emission images (λex = 543 nm, λem = 576 – 619 nm), F. 
fluorescein emission image, G. stain emission images. Slice thickness: 0.37 µm. Scale 
bars: 5 µm. Images are representative of duplicates experiments carried out on different 
days.  
 
Figure 53 displays a Z-staking experiment. The fluorescence within the nucleus in 
every plane confirms that the triple fluorescein labelled dendron NLS probe 3-65 
stains the nucleus. Bright fluorescent pocket observed within the nucleus suggesting 
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This chapter aimed to better understand the behaviour of dendron delivery vehicles 
in their ability to penetrate the nucleus. Successful synthesis of two fluorescein 
labelled NLS peptides 60 and 62 and two fluorescein labelled tri-branched NLS 
dendrons 65 and 67 were carried out, with findings associated to their endocytic and 
nuclear uptake discussed. A combination of cellular delivery structures with multiple 
NLS sequences is not sufficient for nuclear delivery, as it can remain entrapped in 
endosomes. The cellular delivery system must be carefully chosen to prevent the 
conjugate from being captured in endosomes, and ensure release into the cytoplasm. 
The increased number of fluorescein molecules on the probe has greatly improved 
the cellular delivery and allowed nuclear delivery, confirming that subtle structural 
differences have considerable consequences on internalisation mechanisms and 
cellular/nuclear localisation. Therefore, the development of this vector can be further 
investigated in varied cell lines or in conjugation to a cargo of interest. 
 
  





Conclusion and Future Work 
 
The aim of this thesis was to contribute to the field of fluorescent imaging by the 
development of imaging probes, as well as improving the synthesis and purity of 
well-known dyes such as fluorescein and rhodamine. Previously in the Bradley group 
self-quenched dendrons were developed. To broaden their applications and further 
understand their mode of action, the first aim of this thesis was to study the dendron 
core with respect to cell permeability and solubility and to then develop a synthesis 
for a “dual-colour” self-quenched dendron for the detection of human neutrophil 
elastase. The second aim of this thesis was to establish a single isomer synthesis of  
5- and 6-carboxyfluoresceindiacetate N-succinimidyl ester (CFDA-SE) as well as  
5- and 6-carboxytetraethylrhodamine N-succinimidyl ester, as the use of single 
isomer would allow the development of purer and more fluorescent probes. The final 
aim was to synthesise and investigate the nuclear labelling properties of the dendron 
structure when conjugated to nuclear localisation sequences (NLS). 
In chapter 2, six non peptidic probes were synthesised for the investigation of the 
dendron core structure. After the synthesis was optimised, cell studies showed that 
the dendron core, labelled with fluorescein, diacetylated fluorescein or 
tetraethylrhodamine do not penetrate A549 cells or non-activated neutrophils. On 
neutrophil activation, the diacetylated fluorescein labelled dendron entered the cells. 




A synthesis for a dual labelled dendron-based probe specific to neutrophil elastase 
was developed and its cleavage by the target enzyme was confirmed by enzyme 
kinetics studies. This peptidic probe was cleaved in the presence of activated 
neutrophils resulting in a fluorescence signal but was not cleaved in the presence of 
non-activated neutrophils, nor in the presence of activated neutrophils with elastase 
inhibitor, confirming probe specificity to elastase. This probe should be further 
investigated, carrying out in vivo experiments using an endoscopic fluorescence 
system for the detection of neutrophils in lungs. The concept should also be exploited 
using a different peptide sequence for the detection of other proteases such as 
cathepsin G or protease 3. 
In chapter 3, 5-CFDA-SE-53 and 6-CFDA-SE-54 were successfully synthesised and 
separated in a simple two step procedure. A method for generating the single isomers 
5-Rho-SE-50 and 6-Rho-SE-51 has also been established. The cellular labelling 
properties of the four isomers were compared using primary T cells and a Jurkat cell 
line. In both cell types the 5-CFDA-SE-53 labelled cells showed better cellular 
labeling than 6-CFDA-SE-54 labelled cells.  
5-Rho-SE-50 and 6-Rho-SE-51 successfully labelled the cyplotasmic protein of T 
cells and Jurkat cells, and were passed onto daughter cells in a similar fashion to 
CFDA-SE. The studies suggest that 5-Rho-SE-50 can be used for cell division if a 
higher wavelength is more convenient.  
The development of this single isomer synthesis is obviously an advantage in terms 
of probe synthesis as its use would lead to purer reactions and simpler analyses. In 




the future, fluorescein labelled probes should be developed using single isomers. For 
the use of the single isomer of CFDA-SE in proliferation assays, further studies 
should be carried out to completely confirm the superiority of 5-CFDA-SE-53 over  
6-CFDA-SE-54, such experiments should include the labelling of T cells grown in 
vivo, and proliferation assays on a library of cell types. 
In chapter 4, successful synthesis of two fluorescein labelled NLS peptides and two 
fluorescein labelled tri-branched NLS dendrons were carried out. Studies on A549 
cells showed that NLS sequences labelled with fluorescein did not enter the cell 
within 2 h. Tri-branched NLS dendrons labelled with one fluorescein moiety do enter 
the cell but remain entrapped in endosomes, however, tri-branched NLS dendrons 
labelled with three fluorescein moieties does enter the cell as well as the nucleus 
within 2 h. The dendron structures developed in chapter 2 offer two points of 
functionalisation, therefore, future experiments should functionalise this fluorescent 
nuclear penetrating dendron further, with the attachment of a cargo to investigate the 
nuclear delivery properties of this construct, in various cell types. 
 
  







Solvents and reagents were obtained from commercial suppliers and used as 
received. Reactions involving moisture sensitive reagents were performed under a 
positive pressure of dry nitrogen, and the glassware used was oven dried and cooled 
under dry nitrogen prior to the experiment. Reactions involving light sensitive 
compounds were kept under aluminium foil at all times.  
Microwave assisted heating reactions were performed in sealed heavy-walled 
Pyrex tubes using a Biotage Initiatior Microwave. Microwave irradiation was 
conducted at 2.45 Hz for a fixed temperature and pressure followed by thin layer 
chromatography (TLC), and/or analytical reverse-phase high-performance liquid 
chromatography (RP-HPLC) and/or Electrospray ionization mass spectrometry  
(ESI-MS).  
Removal of solvents was performed at reduced pressure, using a Büchi rotary 
evaporator.  
 TLC was carried out on aluminium sheets precoated with silica gel 60 F254 
and were visualised at 254 nm and 344 nm and/or stained with ninhydrin (0.3% 
ninhydrin in n-butanol and 3% acetic acid). 
Column chromatography was performed using glass columns and silica gel 
60 (mesh 0.040-0.063).  




Solid-phase synthesis was carried out in polypropylene syringes equipped 




C nuclear magnetic resonance spectra were recorded on automated 
Bruker instruments: ARX250 (250 and 63 MHz respectively), DPX360 (360 and  
90 MHz respectively), AV400 (400 and 100 MHz respectively), AV500 (500 and 
126 MHz respectively). Chemical shifts (H and C) are quoted in parts per million 
(ppm) relative to the residual solvent signal and all coupling constants (J) given in 
Hertz (Hz). Resonances were characterised as singlet (s), broad singlet (bs), doublet 
(d), doublet of doublet (dd), triplet (t), quartet (q), quintet (quint) or multiplet (m).
  
Analytical reverse-phase high-performance liquid chromatography (RP–
HPLC) was conducted on an Agilent Technologies 1100 modular HPLC system 
coupled to a Polymer Lab 100 ES Evaprorative Scattering Detector (ELSD), with 
detection at 220, 254, 260, 282 and 495 nm. Column: Supelco Discovery® C18,  
5 μm particle size, reverse-phase (5 cm × 4.6 mm) with a flow rate of 1 mL/min or 
Poroshell 120, SB-C18 4.6 × 50 mm. Solvents used were HPLC grade and 
supplemented with 0.1% formic acid.  
Method 1: 5 min method starting from water/MeOH 95:5 gradient to 5:95 over 
3 min, then 1 min isocratic, 1 min back to the original values. 
Method 2: 5 min method starting from water/MeCN 95:5 gradient to 5:95 over 
3 min, then 1 min isocratic, 1 min back to the original values. 
Method 3: 15 min method starting from water/MeOH 95:5 gradient to 5:95 
over 10 min, then 4 min isocratic, 1 min back to the original values. 




Method 4: 15 min method starting from water/MeCN 95:5 gradient to 5:95 
over 10 min, 4 min isocratic, 1 min back to the original values. 
Method 5: 15 min method starting from water/MeCN 95:5 gradient to 5:95 
over 10 min, 4 min isocratic, 1 min back to the original values. 
Semi-preparative RP–HPLC was performed on an Agilent Technologies 
HP1100 Chemstation equipped with a Phenomenex Prodigy C18, 5 μm particle size, 
reverse-phase column (250 × 10 mm,) with a flow rate 2 mL/min and eluting 
following method 6 or 7. 
Method 6: 50 min method starting from water/MeOH 95:5 gradient to 5:95 
over 30 min, 10 min isocratic, then 1 min back to the original values. 
Method 7: 50 min method starting from water/MeCN/FA 95:5 to 5:95 over 30 
min, 10 min isocratic, 1 min back to the original values. 
Electrospray ionization mass spectrometry (ESI–MS) analyses were 
acquired on a VG platform single quadrupole electrospray ionozation mass 
spectrometer. 
High Resolution Mass Spectra (HRMS) were performed on a Finnigan MAT 
900 XLP high resolution double-focussing mass spectrometer. 
Matrix assisted laser desorption ionisation-time of flight (MALDI-TOF) 
mass spectrometry was carried out using an Applied Biosystems Voyager-DE™ STR 
and analysed with the Voyager Instrument Control Panel software. Sinapic acid was 
used as a matrix solution (10 mg/mL) in 50% MeCN in water with 0.1% TFA. 




Fourier Transform Infrared Spectroscopy (FTIR) spectra were obtained 
using neat compounds on a Fourier transform IR Bruker Tensor 27 
spectrophotometer with a golden gate accessory.  
Melting points were determined using a Gallenkamp melting point apparatus.  
Qualitative ninhydrin test:
150
 3 drops of reagent A and 1 drop of reagent B 
are added to a few beads of interest and allowed to sit at 110 °C for 3 min. Solution 
A (1.3 mg KCN in water (2 mL), phenol : EtOH (8 : 2: 50 mL), freshly distilled 
pyridine (100 mL)) and Solution B (2.5 g ninhydrin in EtOH (50 mL)). 




Unless stated otherwise, all solid phase protocols were carried out on resin (100 mg) 
preswollen in DCM (3 mL) for 10 min. Peptide couplings, deprotections and capping 
reactions were stopped by collection of the resin by filtration and washing of the 
resin with DMF (3 × 10 mL), DCM (3 × 10 mL), and MeOH (3 × 10 mL).  
All peptides were built using standard Fmoc strategy with attachment of the amino 
acid using Oxyma or HBTU followed by Fmoc deprotection.  
Cleavage reactions were carried out using 2 mL of the cleavage solution and stopped 
by collection of the cleavage solution from the resin by filtration and removal of the 
volatiles under reduced pressure. 
P1) Pre-activation of 2-chlorotrityl linker: to 2-chlorotrityl linker 
functionalised resin (300 mg), 1 mL of thionyl chloride in DCM (1:2) was added and 




the reaction stirred for 30 min. The resin was then washed with dry DCM (2 × 5 
mL). 
P2) Diamine linker attachment to the 2-chlorotrityl linker:
157
 The resin 
(100 mg) was preswollen in dry DCM (2 mL; 1 min), and a solution of diamine (10 
eq, 5 M) with DIPEA (10 eq) in dry DMF was added and shaken for 1 h. 
P3) Coupling of isocyanate 4 to amine functionalised resin: Isocyanate 4 
(50 mg, 0.06 mmol), DIPEA (10 μL, 0.06 mmol) and 4-dimethylaminopyridine 
DMAP (2 mg, 0.02 mmol) were dissolved in DCM (2 mL) and DMF (2 mL) and 
added to the desired amine functionalised resin and the mixture shaken for 12 h.  
P4) Hydrazine Dde Deprotection: The resin (100 mg) was stirred (6 × 5 min) 
with 4% hydrazine in DMF (v/v) (4 mL). Between each hydrazine treatment the resin 
was washed with DCM (5 mL).  
P5) Oxyma coupling: Oxyma (3 eq) was added to a solution of Fmoc 
protected amino acid (3 eq) in DMF (0.1 M), and stirred for 10 min. DIC (4 eq) was 
then added and the mixture stirred for a further 3 min. The coupling solution was 
added to the corresponding resin (1 eq, 100 mg), and shaken for 1 h.  
P6) HBTU coupling: O-Benzotriazole-N,N,N’,N’-tetramethyl-uronium-
hexafluoro-phosphate HBTU (5 eq) and DIPEA (10 eq) were added to the solution of 
Fmoc protected amino acid (5 eq) in DMF (0.1 M), and stirred for 3 min. The 
coupling solution was added to the corresponding resin (1 eq, 200 mg) and shaken 
for 1 h.  
P7) Fmoc Deprotection: The resin (100 mg) was stirred (2 × 10 min) with 
20% piperidine in DMF (v/v) (2 mL).  




P8) Capping: The resin (100 mg) was treated with 2 mL of a solution of DMF, 
pyridine and Ac2O (15:3:2) and stirred (2 × 10 min). 
P9) Carboxyfluorescein diacetate N-succinimidyl ester solid phase 
coupling: To the resin (100 mg) was added a solution of carboxyfluorescein 
diacetate  
N-succinimidyl ester (3 eq, 0.01 M), DIPEA (2 eq) in dry DCM. The reaction was 
shaken for 2 h. The resin was then washed with dry DCM (3 × 5 mL). 
P10) TFA cleavage cocktail for organic compounds: The resin was treated 
with TFA/DCM/H2O (95: 2.5: 2.5) and stirred for 3 h.  
P11) TFE procedure for cleavage of protected molecules from a resin: The 
resin was treated with a solution of TFE/AcOH/DCM (1:1:3) and stirred for 1 h.  
P12) HFIP procedure for cleavage of protected molecules from a resin: 
The resin was treated with 30% HFIP in DCM (v/v) and stirred for 3 h. Hexane (3 
mL) added prior to the removal of volatiles. 
P13) TFA cleavage cocktail for peptidic compounds: The resin was treated 
with 2 mL of TFA: Phenol: H2O: Triisopropylsilane (88:5:5:2) for 3 h. Peptide 
precipitated by addition of cold diethyl ether. 
Solution phase: 
P14) Carboxyfluorescein diacetate N-succinimidyl ester solution phase 
coupling: The amine (1 eq) was dissolved in dry DMF/MeCN (9:1; 0.01 M) and 
DIPEA (2 eq) added. Carboxyfluorescein diacetate N-succinimidyl ester (or 
carboxytetraethylrhodamine N-succinimidyl ester) (1.2 eq) was dissolved in dry 




DMF/MeCN (9:1; 0.02 M) and added to the solution of the amine. The reaction was 
stirred for 2 h. 
P15) Acetyl group deprotection: The compound of interest (20 mg) was 
dissolved in 20% piperidine in DMF (v/v) (0.5 mL), and stirred for 30 min. DMF 
was removed under reduced pressure. 
 






To a stirred solution of tris(hydroxymethyl)aminomethane (6.0 g, 49.6 mmol) in 
THF (100 mL), was added aqueous KOH (40%, 2 mL) followed by acrylonitrile  
(13 mL, 198.2 mmol) and distilled water (5 mL) and the resulting solution stirred for 
24 h. After concentrating under reduced pressure, water (20 mL) was added, the 
aqueous layer was extracted with DCM (3 × 60 mL). Organic layers were combined 
and washed with brine (40 mL). After drying over Na2SO4 the solvents were 
evaporated under reduced pressure to yield amine 6 as a colourless oil (10.7 g, 77%).  
HPLC: 0.82 min (method 1). Purity ≥ 99% by ELSD detection. 
m/z (ES
+
): C13H20N4O3 calculated 280.3, found 281.2 [M+H]
+
 (100%). 





H NMR (360 MHz, CDCl3) δH 3.67 (t, J = 6.0 Hz, 6H, Alkyl-H), 3.43 (s, 6H, 
Alkyl-H), 2.62 (t, J = 6.0 Hz, 6H, Alkyl-H), 1.96 (s, 2H). 
13
C NMR (90 MHz, CDCl3) δC 117.7 (C), 71.9 (CH2), 65.3 (CH2), 55.7 (C), 18.4 
(CH2). 









Amine 6 (4.5 g, 16.1 mmol) in THF (100 mL) was cooled to 0 ºC. A solution of 
Boc2O (5.3 g, 24.1 mmol) and DIPEA (4.2 mL, 24.1 mmol) in THF (60 mL) was 
added. The solution was allowed to warm to room temperature and was stirred for  
16 h before being concentrated under reduced pressure. EtOAc (100 mL) was added 
and the solution washed with aqueous KHSO4 (1 M, 50 mL), saturated aqueous 
NaHCO3 (2 × 80 mL) and brine (50 mL). Organic layers were dried over Na2SO4 and 
concentrated under reduced pressure to yield carbamate 7 as a colourless oil (6.0 g, 
98%).  





 calculated 403.4, found 403.0 [M+Na]
+
 (100%). 





H NMR (250 MHz, CDCl3) δH 4.82 (s, 1H), 3.73 (s, 6H, Alkyl-H), 3.65 (t, J = 6.0 
Hz, 6H, Alkyl-H), 2.58 (t, J = 6.0 Hz, 6H, Alkyl-H), 1.48 (s, 9H, Alkyl-H)  
13
C NMR (62.5 MHz, CDCl3) δC 155.7 (C), 117.7 (C), 79.1 (C), 68.9 (CH2), 65.4 
(CH2), 58.1 (C), 27.9 (CH3), 18.4 (CH2). 




[2-(2-amino-ethoxy)-1,1-bis-(2-cyano-ethoxymethyl)-ethyl]-carbamic acid tert- 
butyl ester (25) 
 
A solution of BH3.THF (1 M, 47.5 mL, 48.15 mmol) was added slowly to a solution 
of tris-(nitrile)amine 7 (3.0 g, 8.03 mmol) in THF (20 mL) and the resulting solution 
was stirred at reflux for 5 h. After cooling, aqueous HCl (2 M) was added dropwise 
until pH 1-2 was reached. The solution was neutralised with aqueous NaOH (1 M) 
and solvents removed under reduced pressure. The crude product 25 was carried onto 

















The crude product 25 was dissolved in MeOH (50 mL) and  
N,N-diisopropylethylamine (DIPEA) (1 mL, 5.74 mmol) was added. A solution of 
DdeOH-10 (5.8 g, 32.1 mmol) in MeOH (10 mL) was added and the reaction 
mixture stirred for 16 h. The reaction mixture was poured into brine and extracted 
with DCM (2 × 250 mL). The combined organics were washed with water (2 × 200 
mL), brine (200 mL), dried over Na2SO4 and concentrated under reduced pressure. 
Purification by column chromatography [eluting solvent: DCM:MeOH (1:0 to 19:1)] 
yielded  
tris-enamine 8 as a brown oil (1.8 g, 22%).  
HPLC: Rt 4.62 min (method 1). Purity ≥ 99% by ELSD detection. 
m/z (ES
+
): C48H76N4O11 calculated 884.6, found 885.2 [M+H]
+









H NMR (360 MHz, CDCl3) δH 3.60 (s, 6H, Alkyl-H), 3.47 (t, J = 6.0 Hz, 6H, 
Alkyl-H), 3.42 (t, J = 5.8 Hz, 6H, Alkyl-H), 2.50 (s, 9H, Alkyl-H), 2.29 (s, 12H, 
Alkyl-H), 1.86 (quint, J = 6.1 Hz, 6H, Alkyl-H), 1.34 (s, 9H), 0.96 (s, 18H, Alkyl-
H). 
13
C NMR (90 MHz, CDCl3) δC 198.5 (C), 173.5 (C), 154.9 (C), 107.9 (C), 79.1 (C), 
69.8 (CH2), 68.3 (CH2), 58.5 (C), 53.5 (CH2), 40.6 (CH2), 30.9 (C), 30.1 (CH3), 29.3 
(CH2), 28.5 (CH3), 17.8 (CH3). 










Dimedone 9 (10.0 g, 71 mmol), DMAP (11.64 g, 95 mmol) and 1-ethyl-3-(3- 
dimethylaminopropyl)carbodiimide hydrochloride EDCI.HCl (18.27 g, 95 mmol) 
were dissolved in DMF (160 mL). Acetic acid (5.45 mL, 95 mmol) was added and 
the resulting solution stirred for 16 h. The resulting yellow/orange solution was 
concentrated under reduced pressure. EtOAc (400 mL) was added and the organics 
washed with aqueous HCl (1 M, 150 mL), aqueous KHSO4 (1 M, 150 mL), water 
(150 mL) and brine (150 mL). The organic layer was dried over Na2SO4 and 
concentrated under reduced pressure to give the crude as a yellow oil that solidified 




on standing. Purification by column chromatography [eluting with hexane/EtOAc 
(6:4)] yielded DdeOH-10 as a yellow solid (10.67 g, 65%).  
HPLC: 4.28 min (method 1). Purity ≥ 99% by ELSD detection. 
m/z (ES
+
): C10H14O3 calculated 182.2, found 183.1 [M+H]
+





H NMR (400 MHz, CDCl3) δH 2.56 (s, 3H, Alkyl-H), 2.48 (s, 2H, Alkyl-H), 2.31 
(s, 2H, Alkyl-H), 1.03 (s, 6H, Alkyl-H). 
13
C NMR (100 MHz, CDCl3) δC 202.3 (C), 197.8 (C), 195.1 (C), 112.3 (C), 52.4 
(CH2), 46.8 (CH2), 30.5 (CH3), 28.4 (CH3), 28.1 (CH3). 
m.p.: 36 – 37 ºC 














A solution of carbamate 8 (1.75 g, 1.98 mmol) in 20% TFA/DCM (30 mL) was 
stirred for 2 h. After concentration under reduced pressure, DCM (150 mL) was 
added and the solution neutralised with saturated aqueous sodium carbonate (250 
mL). Extraction with DCM (3 × 150 mL) and the combined organic layers were 
washed with brine, dried over Na2SO4 and concentrated under reduced pressure to 
yield amine 11 as a colourless oil (1.32 g, 85%).  
HPLC: 3.77 min (method 1). Purity ≥ 99% by ELSD detection. 
m/z (ES
+




H NMR (250 MHz, CDCl3) δH 3.50 – 3.44 (m, 12H, Alkyl-H), 3.32 (s, 6H, Alkyl-
H) 2.53 (s, 9H, Alkyl-H), 2.32 (s, 12H, Alkyl-H), 1.93 – 1.86 (m, 6H, Alkyl-H), 0.99 
(s, 18H, Alkyl-H). 
13
C NMR (62.5 MHz, CDCl3) δC 197.4 (C), 173.5 (C), 107.9 (C), 72.9 (CH2), 68.6 
(CH2), 56.2 (C), 53.5 (CH2), 40.8 (CH2), 31.0 (C), 29.3 (CH2), 28.3 (CH3), 17.9 
(CH3).  








p-Hydroxybenzaldehyde (2 g, 16.4 mmol), K2CO3 (3.6 g, 18.0 mmol), KI (5 mg, 0.3 
mmol) were stirred in CH3CN (50 mL) for 15 min. Ethyl bromoacetate (3.01 g, 19.7 
mmol) was added dropwise and the resultant mixture was refluxed for 16 h. After 
cooling, CH3CN was removed under reduced pressure. EtOAc (30 mL) was added 




and the organic layers washed with aqueous NaOH (1 M, 20 mL), water (20 mL) and 
brine (20 mL). The organic layer was dried over Na2SO4 and solvent evaporated 
under reduced pressure to yield aldehyde 68 as a pale yellow oil (2.5 g, 78%). 
HPLC: 3.33 min (method 1). Purity ≥99% by ELSD detection. 
m/z (ES
+




H NMR (400 MHz, CDCl3) δH 9.65 (s, 1H), 7.61 (dd, J = 8.8, 2.0 Hz, Ar-H), 6.83 
(dd, J = 8.8, 2.0 Hz, Ar-H), 4.53 (s, 2H, Alkyl-H), 3.57 (s, 3H, Alkyl-H) 
13
C NMR (100 MHz, CDCl3) δC 190.1 (CH), 167.9 (C), 161.9 (C), 131.2 (C), 130.0 
(CH), 114.2 (CH), 64.3 (CH2), 51.5(CH3). 










To a solution of aldehyde 68 (1.8 g, 9.2 mmol) in MeOH (55 mL), sodium 
borohydride (352 mg, 9.2 mmol) was added at 0 °C. The reaction was stirred for 2 h 
before concentrating under reduced pressure. EtOAc (20 mL) was added and organic 
layer washed with aqueous HCl (1 M, 20 mL), aqueous KHSO4 (1 M, 20 mL), water 
(20 mL), and brine (20 mL), dried over MgSO4 and concentrated under reduced 
pressure. Purification by column chromatography [eluting with hexane-EtOAc (1:0 
to 6:4)] yielded alcohol 14 (0.9 g, 50%) as a white solid. 




HPLC: 3.09 min (method 1). Purity ≥ 99% by ELSD detection. 
m/z (ES
+




H NMR (400 MHz, CDCl3) δH 7.29 (dt, 2H, J = 8.8, 2.0 Hz, 2H, Ar-H), 6.90 (dt, 
2H, J = 8.8, 2.0 Hz, 2H, Ar-H), 4.64 (s, 2H, Alkyl-H), 4.61 (s, 2H, Alkyl-H), 3.81 (s, 
3H, Alkyl-H). 
13
C NMR (100 MHz, CDCl3) δC 169.3 (C), 157.2 (C), 134.3 (C), 128.5 (CH), 114.6 
(CH), 65.3 (CH2), 64.6 (CH2), 52.2 (CH3). 
Mp: 44 – 45 ºC 




[4-(4-Nitro-phenoxycarbonyloxymethyl)-phenoxy]-acetic acid methyl ester (15) 
 
Benzylic alcohol 14 (1.20 g, 6.12 mmol) was dissolved in dry DCM (18 mL), dry 
pyridine was added (985 µL, 12.23 mmol) and the reaction cooled to 0 ºC. After  
10 min stirring a solution of 4-nitrophenyl chloroformate (2.47 g, 12.23 mmol) in dry 
DCM (7 mL) was added dropwise and the reaction stirred for 2 h at 0 ºC. The 
resulting cloudy solution was filtered and the filtrate dried over Na2SO4. Purification 
by column chromatography [eluting solvent: Hexane:EtOAc (8:2)] yielded the nitro 
compound 15 as a white solid (1.48 g, 67%). 
HPLC: 4.21 min (method 2). Purity ≥ 99% by ELSD detection. 
m/z (ES
+
): C17H15NO8 calculated 361.3, found 384.0 [M+Na]
+
 (100%). 






): C17H15NO8Na1 calculated [M+Na]
+ 
384.06899, found 384.06860.  
1
H NMR (400 MHz, CDCl3) δH 8.24 (dt, J = 9.2, 2.7 Hz, 2H, Ar-H), 7.39 – 7.32 (m, 
4H, Ar-H), 6.91 (dt, J = 8.7, 2.5 Hz, 2H, Ar-H), 5.21 (s, 2H, Alkyl-H), 4.64 (s, 2H, 
Alkyl-H), 3.79 (s, 3H, Alkyl-H). 
13
C NMR (100 MHz, CDCl3) δC 169.3 (C), 158.6 (C), 155.7 (C), 152.6 (C), 145.6 
(C), 130.9 (CH), 127.7 (C), 125.5 (CH), 122.0 (CH), 115.0 (CH), 70.9 (CH2), 65.4 
(CH2), 52.5 (CH3). 
Mp: 77 – 78 ºC. 





carbamoyloxy)-methyl}-phenoxy-acetic acid methyl ester (17) 
 
Carbonate 15 (755 mg, 2.09 mmol) was dissolved in dry DCM (20 mL), dry pyridine 
(1.4 mL, 20.91 mmol) and DMAP (2 mg, catalytic amount) were added and the 
solution cooled to 0 ºC. A solution of mono Dde protected diaminoctane 16 (687 mg, 
1.74 mmol) in dry DCM (145 mL) was added slowly. The reaction was warmed to 
room temperature and stirred for 5 h. The reaction was monitored by TLC using 
ninhydrin staining. The reaction mixture was washed with water (20 mL), 1 M 
KHSO4 (2 × 20 mL), and brine (20 mL). Purification by column chromatography 




[eluting solvent: Hexane:EtOAc (7:3 to 3:7)] yielded 17 as a colourless oil (473 mg, 
40%). 
HPLC: 4.17 min (method 1). Purity ≥ 99% by ELSD detection. 
m/z (ES
+
): C27H38N2O7 calculated 502.6, found 503.3 [M+H]
+











H NMR (400 MHz, CDCl3) δH 13.39 (s, 1H), 7.26 (d, J = 8.6 Hz, 2H, Ar-H), 6.84 
(dt, J = 8.7, 2.4 Hz, 2H, Ar-H), 4.98 (s, 2H, Alkyl-H), 4.83 (bs, 1H), 4.59 (s, 2H, 
Alkyl-H), 3.76 (s, 3H, Alkyl-H), 3.36 (dt, J = 6.6, 5.6 Hz, 2H, Alkyl-H), 3.14 (dt, J = 
6.6, 6.4 Hz, 2H, Alkyl-H), 2.51 (s, 3H, Alkyl-H), 2.32 (s, 4H, Alkyl-H, 1.67 – 1.60 





C NMR (100 MHz, CDCl3) δC 198.1 (C), 173.6 (C), 169.4 (C), 157.8 (C), 156.6 
(C), 130.2 (CH), 114.8 (CH), 108.0 (C), 66.3 (CH2), 65.5 (CH2), 53.0 (CH2), 52.4 
(CH3), 43.5 (CH2), 41.0 (CH2), 30.3 (C), 29.9 (CH2), 29.0 (CH2), 28.4 (CH3), 26.6 
(CH2), 26.4 (CH2), 18.1 (CH3). 













carbamoyloxy)-methyl}-phenoxy-acetic acid (12) 
 
To a solution of ester 17 (355 mg, 0.71 mmol, 0.1 M) in MeOH (3.5 mL) was added 
dropwise a 2 M Cs2CO3 aqueous solution (3.5 mL) and the reaction stirred for 2 h. 
MeOH was removed under reduced pressure and the residue was dissolved in water 
(15 mL). 1 M KHSO4 was added (pH 5-6) and the solution washed with EtOAc  
(15 mL). The aqueous solution was extracted three times with DCM (3 × 10 mL). 
Organic layers were combined, dried over Na2SO4 and concentrated under reduced 
pressure to give the desired compound 12 as a yellow solid (345 mg, 99%). 
HPLC: 4.15 min (method 1). Purity ≥ 99% by ELSD detection. 
m/z (ES
+
): C26H36N2O7 calculated 488.57, found 489.3 [M+H]
+
 (35%), 511.3 
[M+Na]
+
 (10%).  
m/z (HRMS, ES
+





H NMR (400 MHz, CDCl3) δH 13.29 (bs, 1H), 7.26 (d, J = 8.5 Hz, 2H, Ar-H), 6.86 
(d, J = 8.6 Hz, 2H, Ar-H), 4.99 (s, 2H, Alkyl-H), 4.88 (bs, 1H), 4.61 (s, 2H, Alkyl-
H), 3.40 – 3.27 (m, 2H, Alkyl-H), 3.20 – 3.08 (m, 2H, Alkyl-H), 2.51 (s, 3H, Alkyl-
H), 2.35 (s, 4H, Alkyl-H), 1.68 – 1.57 (m, 2H, Alkyl-H), 1.50 – 1.43 (m, 2H, Alkyl-
H), 1.39 – 1.25 (m, 4H, Alkyl-H), 1.00 (s, 6H, Alkyl-H). 





C NMR (100 MHz, CDCl3) δC 198.5 (C), 174.2 (C), 171.3 (C), 157.9 (C), 156.8 
(C), 130.2 (CH), 114.8 (CH), 108.0 (C), 66.4 (CH2), 65.3 (CH2), 52.6 (CH2), 43.7 
(CH2), 40.9 (CH2), 30.4 (C), 29.9 (CH2) 29.0 (CH2), 28.4 (CH3), 26.6 (CH2), 26.3 
(CH2), 18.4 (CH3). 
IR (neat): 1684 (m, νC=O), 1573 (m, νN-H), 1429 (m, νO-H), 1243 (m, νC-OH) cm
-1
. 
Mp: 80 – 82 ºC. 
 
Attachment of the Linker to the aminomethyl TentaGel resin and Dde 
deprotection (69) 
 
Linker 12 was attached to aminomethyl TentaGel resin (loading value:  
0.45 mmol.g
-1
, particle size: 150-200 µm) using the Oxyma coupling protocols P5 


















A solution of Boc2O (19.5 mg, 0.09 mmol) in anhydrous DCM (1 mL) was added 
dropwise to a solution of monomer 11 (50 mg, 0.06 mmol) and DMAP (8.6 mg, 0.01 
mmol) in anhydrous DCM (1 mL). The resulting solution was stirred for 1 h, the 
solvent was removed under reduced pressure and used immediately. 





): C44H66N4O10 calculated 811.0, found 811.3 [M]
+




















yl)urea (20)  
 
The isocyanate 4 was attached to resin 69 (50 mg, 0.3 mmol.g
-1
) and Dde groups 
removed following protocol P4. 5(6)-Carboxyfluorescein was attached using Oxyma 
protocol P5. Compound 20 was cleaved from the linker using TFA protocol P10  
(22 mg, 16%). 
m/z (ES
+
): C83H76N6O22 calculated 1509.5, found 1509.3 [M+H]
+
 (10%). 









1,2-Diaminoethane was attached to the activated 2-chlorotrityl linker polystyrene 
resin (30 mg, 1.4 mmol.g
-1
, particle size 100-200 mesh) (protocols P1 and P2). The 
isocyanate 4 was then attached and the Dde groups removed (protocols P3 and P4). 
The resulting amine moiety was acylated and the compound was cleaved from the 
linker using TFA (protocols P8 and P10) (21 mg, 64%).  
HPLC: 0.88 min using method 1. Purity ≥ 99% by ELSD detection. 
m/z (ES
+
): C22H44N6O7 calculated 504.6, found 505.4 [M+H]
+





H NMR (500 MHz, CD3OD) δH 3.66 (s, 6H, Alkyl-H), 3.47 (t, J = 6.0 Hz, 6H, 
Alkyl-H), 3.34 – 3.32 (m, 2H, Alkyl-H), 3.26 (dd, J = 8.3, 5.6 Hz, 6H, Alkyl-H), 










1,8-Diaminooctane was attached to the activated 2-chlorotrityl linker polystyrene 
resin (30 mg, 1.4 mmol.g
-1
) (protocols P1 and P2). The isocyanate 4 was then 
attached and the Dde groups removed (protocols P3 and P4). The resulting amine 
moiety was acylated and the compound was cleaved from the linker using TFA 
(protocols P8 and P10) (25 mg, 67%). 
HPLC: 0.90 min using method 1. Purity ≥ 99% by ELSD detection. 
m/z (ES
+




H NMR (500 MHz, CD3OD) δH 3.65 (s, 6H, Alkyl-H), 3.47 (t, J = 6.0 Hz, 6H, 
Alkyl-H), 3.26 (t, J = 6.8 Hz, 6H, Alkyl-H), 3.06 (t, J = 6.9 Hz, 2H, Alkyl-H), 2.91 
(t, J = 7.6 Hz, 2H, Alkyl-H), 1.94 (s, 9H, Alkyl-H), 1.73 (quint, J = 6.4 Hz, 6H, 
Alkyl-H), 1.66 – 1.62 (m, 2H, Alkyl-H), 1.47 – 1.43 (m, 2H, Alkyl-H), 1.40 – 1.34 








4,7,10-trioxa-1,13-tridecanyldiamine was attached to the activated 2-chlorotrityl 
linker polystyrene resin (30 mg, 1.4 mmol.g
-1
) (protocols P1 and P2). The isocyanate 
4 was then attached and the Dde groups removed (protocols P3 and P4). The 
resulting amine moiety was acylated and the compound was cleaved from the linker 
using TFA (protocols P8 and P10) (28 mg, 68%). 
HPLC: 0.86 min using method 1. Purity ≥ 99% by ELSD detection. 
m/z (ES
+




H NMR (500 MHz, CD3OD) δH 3.69 – 3.62 (m, 18H, Alkyl-H), 3.60 – 3.58 (m, 2H, 
Alkyl-H), 3.51 (t, J = 6.1 Hz, 2H, Alkyl-H), 3.47 (t, J = 6.0 Hz, 6H, Alkyl-H), 3.25 
(t, J = 6.9 Hz, 6H, Alkyl-H), 3.16 – 3.09 (m, 4H, Alkyl-H), 1.94 (s, 9H, Alkyl-H), 




Compound 31 (15 mg, 0.030 mmol) was dissolved in DMF (500 µL) and coupled to 
5(6)-carboxyfluorescein using protocol P5. Crude was purified via semi-preparative 
HPLC (method 7) (1.6 mg, 6.3%). 




HPLC: 4.78 min (method 4). Purity ≥ 99% by ELSD detection. 
MALDI-TOF: C43H55N6O13 calculated [M+H]
+




Compound 32 (15 mg, 0.025 mmol) was dissolved in DMF (500 µL) and coupled to 
5(6)-carboxyfluorescein using protocol P5. Crude was purified via semi-preparative 
HPLC (method 7) (1.1 mg, 4.5%). 
HPLC: 4.09 min (method 5). Purity ≥ 99% by ELSD detection. 
MALDI-TOF: C49H67N6O13 calculated [M+H]
+








Compound 33 (20 mg, 0.030 mmol) was dissolved in DMF (500 µL) and coupled to 
5(6)-carboxyfluorescein using protocol P5. Crude was purified via semi-preparative 
HPLC (method 7) (0.8 mg, 2.7%). 
HPLC: 5.00 min (method 4). Purity ≥ 99% by ELSD detection. 
MALDI-TOF: C51H71N6NaO16 calculated [M+Na]
+




Compound 33 (20 mg, 0.030 mmol) was dissolved in DMF (500 µL) and coupled to 
5(6)-carboxyfluorescein using protocol P5. Crude was purified via semi-preparative 
HPLC (method 7) (2.7 mg, 8%). 
HPLC: 4.38 min (method 5). Purity ≥ 99% by ELSD detection. 
MALDI-TOF: C59H88N8NaO14 calculated [M+Na]
+















1,2-Diaminoethane was attached to the activated 2-chlorotrityl linker polystyrene 
resin (30 mg, 1.4 mmol.g
-1
) (protocols P1 and P2). The isocyanate 4 was then 
attached and the Dde groups removed (protocols P3 and P4). The resulting amine 
moiety was acylated and the compound was cleaved from the linker using TFA 
(protocols P8 and P10). The crude mixture was coupled to 6-carboxyfluorescein N-
succinimidyl ester (protocol P14) and purified via semi-preparative HPLC (method 
7) (3.5 mg, 8% over 7 steps). 
HPLC: 8.42 min (method 4). Purity ≥ 99% by ELSD detection. 
m/z (ES
+
): C47H58N6O15 calculated 946.4, found 947.5 [M+H]
+





H NMR (500 MHz, CD3CN) δH 8.31 (bs, 1H), 8.18 (dd, J = 8.1, 1.3 Hz, 1H, Ar-H), 
8.09 (d, J = 8.0 Hz, 1H, Ar-H), 7.69 (bs, 1H, Ar-H), 7.16 (d, J = 2.2 Hz, 2H, Ar-H), 
6.92 (d, J = 8.7 Hz, 2H, Ar-H), 6.88 (dd, J = 8.7, 2.2 Hz, 2H, Ar-H), 6.51 (t, J = 4.8 




Hz, 3H), 6.19 (t, J = 5.5 Hz, 1H), 5.63 (s, 1H), 3.46 (s, 6H, Alkyl-H), 3.32 – 3.29 (m, 
8H, Alkyl-H), 3.24 – 3.22 (m, 2H, Alkyl-H), 3.16 – 3.12 (m, 6H, Alkyl-H), 2.27 (s, 
6H, Alkyl-H), 1.78 (s, 9H, Alkyl-H), 1.60 – 1.55 (m, 6H, Alkyl-H). 
13
C NMR (126 MHz, CD3CN) δC 171.1 (C), 170.3 (C), 166.0 (C), 160.2 (C), 153.7 
(C), 152.7 (C), 152.5 (C), 142.9 (C), 130.7 (C), 130.4 (CH), 129.2 (CH), 126.3 (CH), 
123.4 (C), 119.5 (CH), 117.2 (CH), 111.7 (CH), 71.3 (CH2), 69.4 (CH2), 59.7 (C), 






1,8-Diaminooctane was attached to the activated 2-chlorotrityl linker polystyrene 
resin (30 mg, 1.4 mmol.g
-1
) (protocols P1 and P2). The isocyanate 4 was then 
attached and the Dde groups removed (protocols P3 and P4). The resulting amine 
moiety was acylated and the compound was cleaved from the linker using TFA 
(protocols P8 and P10). The crude mixture was coupled to 5-carboxyfluorescein N-
succinimidyl ester (protocol P14) and purified via semi-preparative HPLC (method 
7) (4.5 mg, 9% over 7 steps).  




HPLC: 8.83 min (method 4). Purity ≥ 99 % by ELSD detection. 
m/z (ES
+
): C53H70N6O15 calculated 1030.5, found 1031.6 [M+H]
+






): C53H70O15N6Na1 calculated [M+Na]
+
 1053.47914, found 
1053.47920.  
1
H NMR (500 MHz, CD3CN) δH 8.42 (d, J = 0.6 Hz, 1H, Ar-H), 8.20 (dd, J = 8.1, 
1.5 Hz, 1H, Ar-H), 7.53 (t, J = 5.4 Hz, 1H), 7.34 (d, J = 8.1 Hz, 1H, Ar-H), 7.14 (d, J 
= 2.1 Hz, 2H, Ar-H), 6.91 (d, J = 8.7 Hz, 2H, Ar-H), 6.87 (dd, J = 8.7, 2.2 Hz, 2H, 
Ar-H), 6.66 (bs, 3H), 5.89 (t, J = 5.0 Hz, 1H), 5.59 (s, 1H), 3.60 (s, 6H, Alkyl-H), 
3.42 – 3.36 (m, 8H, Alkyl-H), 3.24 – 3.20 (m, 6H, Alkyl-H), 3.05 – 3.01 (m, 2H, 
Alkyl-H), 2.26 (s, 6H, Alkyl-H), 1.86 (s, 9H, Alkyl-H), 1.65 – 1.57 (m, 8H, Alkyl-
H), 1.41 – 1.27 (m, 10H, Alkyl-H). 
13
C NMR (126 MHz, CD3CN) δC 171.1 (C), 170.2 (C), 169.3 (C), 166.2 (C), 159.3 
(C), 155.8 (C), 153.7 (C), 152.5 (C), 138.5 (C), 135.8 (CH), 130.2 (CH), 127.5 (C), 
125.2 (CH), 124.7 (CH), 119.5 (CH), 117.2 (C), 111.6 (CH), 71.7 (CH2), 69.5 (CH2), 
59.6 (C), 40.8 (CH2), 40.3 (CH2), 37.1 (CH2), 31.1 (CH2), 30.3 (CH2), 30.1 (CH2), 













1,8-Diaminooctane was attached to the activated 2-chlorotrityl linker polystyrene 
resin (30 mg, 1.4 mmol.g
-1
) (protocols P1 and P2). The isocyanate 4 was then 
attached and the Dde groups removed (protocols P3 and P4). The resulting amine 
moiety was acylated and the compound was cleaved from the linker using TFA 
(protocols P8 and P10). The crude mixture was coupled to 5-carboxyfluorescein N-
succinimidyl ester, the acetyl groups removed (protocols P14 and P15) and purified 
via semi-preparative HPLC (method 6) (4.5 mg 11% over 7 steps).  
HPLC: 8.13 min (method 4). Purity ≥ 99% by ELSD detection. 
m/z (ES
+
): C49H66N6O13 calculated 946.5, found 947.5 [M+H]
+






): C49H66O13N6Na1 calculated [M+Na]
+
 969.45801, found 
969.45330.  
1
H NMR (500 MHz, CD3OD) δH 8.52 (s, 2H), 8.43 (bs, 1H, Ar-H), 8.15 (dd, J = 8.0, 
1.4 Hz, 1H, Ar-H), 7.31 (d, J = 8.0 Hz, 1H, Ar-H), 6.72 (d, J = 8.9 Hz, 2H, Ar-H), 




6.69 (d, J = 2.2 Hz, 2H, Ar-H), 6.77 (dd, J = 8.8, 2.3 Hz, 2H, Ar-H), 3.65 (s, 6H, 
Alkyl-H), 3.49 – 3.40 (m, 8H, Alkyl-H), 3.25 (t, J = 6.8 Hz, 6H, Alkyl-H), 3.07 (t, J 
= 6.8 Hz, 2H, Alkyl-H), 1.93 (s, 9H, Alkyl-H), 1.73 (quint, J = 6.5 Hz, 6H, Alkyl-H), 
1.66 (quint, J = 7.1 Hz 2H, Alkyl-H), 1.50 – 1.33 (m, 10H, Alkyl-H). 
13
C NMR (126 MHz, CD3OD) δC 173.3 (C), 168.7 (C), 165.3 (C), 160.8 (C), 156.6 
(C), 155.4 (C), 141.0 (C), 138.0 (C), 135.4 (C), 130.9 (CH), 128.0 (CH), 126.4 (CH), 
120.8 (CH), 118.0 (CH), 112.3 (C), 103.9 (CH), 71.7 (CH2), 70.0 (CH2), 61.2 (C), 





4,7,10-trioxa-1,13-tridecanyldiamine was attached to the activated 2-chlorotrityl 
linker polystyrene resin (30 mg, 1.4 mmol.g
-1
) (protocols P1 and P2). The isocyanate 
40 was then attached and the Dde groups removed (protocols P3 and P4). The 
resulting amine moiety was acylated and the compound was cleaved from the linker 
using TFA (protocols P8 and P10). The crude mixture was coupled to 5-
carboxyfluorescein N-succinimidyl ester (protocol P15) and purified via semi-
preparative HPLC (method 7). (7.9 mg, 17% over 7 steps).  




HPLC: 7.75 min (method 4). Purity ≥ 99% by ELSD detection. 
m/z (ES
+
): C55H74N6O18 calculated 1107.2, found 1107.4 [M]
+






): C55H74O18N6Na1 calculated [M+Na]
+
 1129.49518, found 
1129.49420.  
1
H NMR (500 MHz, CD3CN) δH 8.41 (bs, 1H, Ar-H), 8.20 (dd, J = 8.0, 1.5 Hz, 1H, 
Ar-H), 7.71 (t, J = 5.3 Hz, 1H), 7.35 (d, J = 8.0 Hz, 1H, Ar-H), 7.15 (d, J = 1.9 Hz, 
2H, Ar-H), 6.91 (d, J = 8.6 Hz, 2H, Ar-H), 6.87 (dd, J = 8.7, 2.1 Hz, 2H, Ar-H), 6.63 
(bs, 3H), 5.89 (t, J = 5.4 Hz, 1H), 5.58 (s, 1H), 3.58 (s, 6H, Alkyl-H), 3.57 – 3.55 (m, 
4H, Alkyl-H), 3.55 – 3.45 (m, 6H, Alkyl-H), 3.42 – 3.36 (m, 8H, Alkyl-H), 3.23 – 
3.18 (m, 6H, Alkyl-H), 3.07 (q, J = 6.3 Hz, 2H, Alkyl-H), 2.27 (s, 6H, Alkyl-H), 
2.10 – 2.05 (m, 2H, Alkyl-H), 1.89 – 1.86 (m, 2H, Alkyl-H), 1.85 (s, 9H, Alkyl-H), 
1.66 – 1.55 (m, 8H, Alkyl-H).
 
13
C NMR (126 MHz, CD3CN) δC 171.06 (C), 170.17 (C), 169.24 (C), 166.24 (C), 
159.24 (C), 155.79 (C), 153.70 (C), 152.49 (C), 138.49 (C), 135.80 (CH), 130.23 
(CH), 127.51 (C), 125.25 (CH), 124.79 (CH), 119.49 (CH), 117.18 (C), 111.60 (CH), 
71.6 (CH2), 71.2 (CH2), 71.1 (CH2), 71.0 (CH2), 70.9 (CH2), 70.1 (CH2), 69.6 (CH2), 
69.5 (CH2), 59.6 (C), 38.8 (CH2), 37.6 (CH2), 37.1 (CH2), 31.3 (CH2), 30.3 (CH2), 











4,7,10-trioxa-1,13-tridecanyldiamine was attached to the activated 2-chlorotrityl 
linker polystyrene resin (30 mg, 1.4 mmol.g
-1
) (protocols P1 and P2). The isocyanate 
4 was then attached and the Dde groups removed (protocols P3 and P4). The 
resulting amine moiety was acylated and the compound was cleaved from the linker 
using TFA (protocols P8 and P10). The crude mixture was coupled to 5-
carboxyfluorescein N-succinimidyl ester, the acetyl groups removed (protocols P4 
and P15) and purified via semi-preparative HPLC (method 6) (10 mg, 23% over 7 
steps).  
HPLC: 7.73 min (method 3). Purity ≥ 99% by ELSD detection. 
m/z (HRMS, ES
+
): C51H71O16N6 calculated [M+H]
+
 1023.49211, found 1023.49190.  
1
H NMR (500 MHz, CD3OD) δH 8.46 (s, 1H, Ar-H), 8.14 (d, J = 7.9 Hz, 1H, Ar-H), 
7.33 (d, J = 8.0 Hz, 1H, Ar-H), 6.79 (d, J = 8.5 Hz, 2H, Ar-H), 6.69 (d, J = 2.0 Hz, 
2H, Ar-H), 6.58 (dd, J = 8.9, 2.1 Hz, 2H, Ar-H), 3.69 – 3.60 (m, 14H, Alkyl-H), 3.56 
– 3.54 (m, 4H, Alkyl-H), 3.44 – 3.49 (m, 8H, Alkyl-H), 3.24 (t, J = 6.8 Hz, 6H, 
Alkyl-H), 3.13 (t, J = 6.7 Hz, 2H, Alkyl-H), 1.94 – 1.92 (m, 2H, Alkyl-H), 1.92 (s, 
9H, Alkyl-H), 1.74 – 1.65 (m, 8H, Alkyl-H). 





C NMR (126 MHz, CD3OD) δC 174.4 (C), 173.3 (C), 168.8 (C), 160.7 (C), 155.9 
(C), 152.7 (C), 143.4 (C), 137.8 (C), 136.3 (C), 131.3 (CH), 128.2 (CH), 124.7 (CH), 
122.2 (CH), 117.7 (CH), 111.3 (C), 104.0 (CH), 71.7 (CH2), 71.6 (CH2), 71.5 (CH2), 
71.4 (CH2), 70.4 (CH2), 70.0 (CH2), 60.2 (C), 40.6 (CH2), 39.1 (CH2), 38.0 (CH2), 




4,7,10-trioxa-1,13-tridecanyldiamine was attached to the activated 2-chlorotrityl 
linker polystyrene resin (30 mg, 1.4 mmol.g
-1
) (protocols P1 and P2). The isocyanate 
4 was then attached and the Dde groups removed (protocols P3 and P4). The 
resulting amine moiety was acylated and the compound was cleaved from the linker 
using TFA (protocols P and P10). The crude mixture was coupled to 6-
carboxytetraethylrhodamine N-succinimidyl ester (protocol P14) and purified via  
semi-preparative HPLC (method 6) (10 mg, 21% over 7 steps). 
HPLC: 6.24 min (method 4). Purity ≥ 99% by ELSD detection. 
m/z (ES
+
): C59H88N8O14 calculated 1133.4, found 1033.7 [M]
+










): C59H89O14N8 calculated [M+H]
+
 1133.64928, found 1133.65130. 
1
H NMR (500 MHz, CD3OD) δH 8.54 (s, 3H), 8.15 (d, J = 8.1 Hz, 1H, Ar-H), 8.08 
(dd, J = 8.1, 1.7 Hz, 1H, Ar-H), 7.71 (d, J = 1.6 Hz, 1H, Ar-H), 7.26 (d, J = 9.5 Hz, 
2H, Ar-H), 7.01 (dd, J = 9.5, 2.4 Hz, 2H, Ar-H), 6.94 (dd, J = 2.3 Hz, 2H, Ar-H), 
3.67 (q, J = 7.1 Hz, 8H, Alkyl-H), 3.63 (s, 6H, Alkyl-H), 3.58 – 3.56 (m, 8H, Alkyl-
H), 3.50 – 3.43 (m, 12H, Alkyl-H), 3.23 (t, J = 6.8 Hz, 6H, Alkyl-H), 3.12 (t, J = 6.7 
Hz, 2H, Alkyl-H), 1.92 (s, 9H, Alkyl-H), 1.89 – 1.86 (m, 2H, Alkyl-H), 1.75 – 1.63 
(m, 8H, Alkyl-H), 1.30 (t, J = 7.1 Hz, 12H, Alkyl-H). 
13
C NMR (126 MHz, CD3OD) δC 179.7 (C), 173.3 (C), 168.7 (C), 160.7 (C), 159.6 
(C), 157.1 (C), 146.7 (C), 144.8 (C), 136.6 (C), 133.2 (CH), 131.3 (CH), 129.7 (CH), 
129.5 (CH), 115.2 (C), 115.1 (CH), 97.2 (CH), 71.6 (CH2), 71.3 (CH2), 70.4 (CH2), 
70.0 (CH2), 60.2 (C), 46.9 (CH2), 39.1 (CH2), 38.0 (CH2), 37.9 (CH2), 31.5 (CH2), 















Protected HNE Peptide (45) 
 
 
The fully protected peptide was synthesised using an automated peptide synthesiser 
Liberty Automatic Microwave Peptide Synthesizer on a L-Glutamine-2-chlorotrityl 
polystyrene resin (100 mg, 0.6 mmol.g
-1
, particle size 100-200 mesh) and the 
cleavage from the linker was carried out using TFE (protocol P11) to give an orange 
oil (18 mg, 15% over 15 steps).  
HPLC: 7.87 min (method 3). Purity ≥ 99% by ELSD detection. 
MALDI-TOF: C95H138N16O23S3Na1 calculated [M+Na]
+













1,8-Diaminooctane was attached to the activated 2-chlorotrityl linker ChemMatrix 
resin (50 mg, 0.65 mmol.g
-1
, particle size 35-100 mesh) (protocols P1 and P2). The 
isocyanate 4 was then attached and the Dde groups removed (protocols P3 and P4). 
Amino acid coupled using Oxyma except the Arginines which were coupled using 
HBTU (protocols P5, P6 and P7). 5-Carboxyfluorescein diacetate N-succinimidyl 
ester was coupled and the compound cleaved from the linker using the HFIP 
(protocols P9 and P12). The resulting compound was coupled to 6-
carboxytetraethylrhodamine  
N-succinimidyl ester and protecting groups removed using TFA cleavage procedure 
for peptidic compound (protocols P14 and P13). The compound was purified via 
semi-preparative HPLC (method 6). (11 mg, 8% over 20 steps).  
HPLC: 8.67 min (method 3); or 5.25 min (method 4). Purity ≥ 99% by ELSD 
detection. 
MALDI-TOF: C216H289N44O56 calculated [M+H]
+ 
4395.1114; Found 4395.0959. 













To a solution of 5(6)-carboxyfluorescein (1.00 g, 2.66 mmol) in Ac2O (12 mL) was 
added pyridine (1.2 mL, 14.9 mmol) and the reaction stirred for 30 min at 110ºC. 
The clear solution was concentrated under reduced pressure. The crude mixture was 
dissolved in EtOAc (20 mL) and washed with aqueous KHSO4 (1 M, 2 × 20 mL) and 
brine (20 mL). The organic layer was dried over Na2SO4, filtered and concentrated 




): C25H16O9 calculated 460.39, found 461.0 [M+H]
+
 (100%).  
m/z (HRMS, ES
+
): C25H16O9Na1 calculated [M+Na]
+ 
483.06865, found 483.06850.  
HPLC: 7.50 and 7.61 min (method 4). Purity ≥ 99% by ELSD detection. 
1
H NMR (500 MHz, CD3CN) δH 8.55 (dd, J = 1.5, 0.8 Hz, 0.5H, Ar-H), 8.34 (dd, J = 
8.1, 1.5 Hz, 0.5H, Ar-H), 8.29 (dd, J = 8.0, 1.4 Hz, 0.5H, Ar-H), 8.1 (dd, J = 8.0, 0.8 
Hz, 0.5H, Ar-H), 7.85 (dd, J = 1.3, 0.8 Hz, 0.5H, Ar-H), 7.38 (dd, J = 8.0, 0.6 Hz, 
0.5H, Ar-H), 7.14 (t, J = 2.3 Hz, 2H, Ar-H), 6.92 – 6.85 (m, 4H, Ar-H), 2.26 (s, 6H, 
Alkyl-H). 





C NMR (500 MHz, CD3CN) δC 170.2 (C), 168.9 (C), 168.9 (C), 166.4 (C), 166.4 
(C), 157.3 (C), 153.9 (C), 153.7 (C), 153.7 (C), 152.6 (C),152.5 (C), 138.2 (C), 137.7 
(CH), 133.7 (C), 132.5 (CH), 130.7 (C), 130.3 (CH), 130.2 (CH) 127.8 (C), 127.5 
(CH), 126.4 (CH), 126.2 (CH), 125.5 (CH), 119.5 (CH), 119.4 (CH), 117.1 (C) 116.9 
(C), 111.6 (CH), 111.6 (CH), 21.3 (CH3). 
Mp: 167 – 169 ºC.
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5(6)-Carboxyfluorescein diacetate (1.00 g, 2.17 mmol) was dissolved in DCM  
(15 mL), HOSu (300 mg, 2.61 mmol) was added and stirred until fully dissolved. 
DIC (410 μl, 2.61 mmol) was added and the reaction stirred at room temperature for 
30 min. The organic layer was washed with water (2 × 10 mL), with brine (10 mL), 
dried over Na2SO4 and filtered. The crude mixture was re-dissolved in toluene  
(10 mL), loaded onto an equilibrated column (4.5 × 15 cm bed of silica) and eluted 
with 20% EtOAc in toluene to afford the pure individual isomers as white solids  
5-isomer (495 mg, 41%) and 6-isomer (505 mg, 42%).  
 




5-Carboxyfluorescein diacetate N-succinimidyl ester (5-CFDA-SE-53) : 
Rf 0.37 in 50:50 EtOAc:Toluene. 
HPLC : 8.56 min (method 4). Purity ≥ 99% 6-isomer <1% by ELSD detection. 
m/z (ES
+
): C29H19N1O11 calculated 557.46, found 558.1 [M+H]
+
 (95%).  
m/z (HRMS, ES
+





H NMR (500 MHz, CDCl3) δH 8.77 (dd, J = 1.5, 0.7 Hz, 1H, Ar-H), 8.38 (dd, J = 
8.1, 1.6 Hz, 1H, Ar-H), 7.33 (dd, J = 8.1, 0.7 Hz, 1H, Ar-H), 7.09 (d, J = 2.2 Hz, 2H, 
Ar-H), 6.82 (dd, J = 8.7, 2.2 Hz, 2H, Ar-H), 6.78 (d, J = 8.7 Hz, 2H, Ar-H), 2.88 (s, 
4H, Alkyl-H), 2.27 (s, 6H, Alkyl-H). 
13
C NMR (126 MHz, CDCl3) δC 169.1 (C), 168.9 (C), 167.4 (C), 160.6 (C), 158.2 
(C), 152.5 (C), 151.5 (C), 137.0 (CH), 129.0 (CH), 128.1 (C), 127.7 (CH), 127.2 (C), 
125.2 (CH), 118.2 (CH), 115.3 (C), 110.8 (CH), 25.8 (CH2), 21.2 (CH3). 
Mp: > 250 ºC.
286
 




6-Carboxyfluorescein diacetate N-succinimidyl ester (6-CFDA-SE-54) : 
Rf 0.53 in 50:50 EtOAc:Toluene 
HPLC: 7.78 min (method 4). Purity ≥ 99% 5-isomer <1% by ELSD detection. 
m/z (ES
+
): C29H19N1O11 calculated 557.46, found 558.2 [M+H]
+
 (100%), 580.2 
[M+Na]
+
 (70%).  
m/z (HRMS, ES
+









H NMR (500 MHz, CDCl3) δH 8.38 (dd, J = 8.0, 1.3 Hz, 1H, Ar-H), 8.16 (d, J = 8.0 
Hz, 1H, Ar-H), 7.91 (s, 1H, Ar-H), 7.12 (d, J = 2.2 Hz, 2H, Ar-H), 6.84 (dd, J = 8.7, 
2.3 Hz, 2H, Ar-H), 6.77 (d, J = 8.7 Hz, 2H, Ar-H), 2.87 (s, 4H, Alkyl-H), 2.30 (s, 
6H, Alkyl-H). 
13
C NMR (126 MHz, CDCl3) δC 168.9 (C), 168.9 (C), 167.6 (C), 160.7 (C), 153.2 
(C), 152.6 (C), 151.8 (C), 132.3 (CH), 131.8 (C), 131.5 (C), 129.1 (CH), 126.5 (CH), 
126.1 (CH), 118.3 (CH), 115.4 (C), 110.9 (CH), 25.8 (CH2), 21.3 (CH3). 

















5(6)-Carboxytetraethyl rhodamine (2.00 g, 4.11 mmol) was purified by column 
chromatography [eluting solvent: TEA:DCM:MeOH (5:95:0 to 5:75:20)]. The two 
separated isomers were obtained as their TEA salts. The 5-isomer salt was 
redissolved in EtOAc (80 mL) and washed with 1 M KHSO4 (3 × 50 mL), with brine 
(50 mL), dried over Na2SO4 and filtered, to afford pure  




5- carboxytetraethylrhodamine 57 (833 mg, 42%) and 6- carboxytetraethylrhodamine 
58 (670 mg, 33%) as dark pink solids. 
5- carboxytetraethylrhodamine 57:  
Rf: 0.11 in 10:89.5:0.5 MeOH:DCM:TEA 
HPLC: 7.54 min (method 4). Purity ≥ 99% by ELSD detection. 
m/z (ES
+





): C26H31N2O5 calculated [M+H]
+ 
487.22275, found 487.22270.  
1
H NMR (500 MHz, CDCl3) δH 8.86 (d, J = 1.0 Hz, 1H, Ar-H), 8.27 (dd, J = 8.0, 1.4 
Hz, 1H, Ar-H), 7.28 (d, J = 8.0 Hz, 1H, Ar-H), 6.91 (d, J = 9 Hz, 2H, Ar-H), 6.60 – 
6.57 (m, 4H, Ar-H), 3.46 (q, J = 7.2 Hz, 8H, Alkyl-H), 1.23 (t, J = 7.1 Hz, 12H, 
Alkyl-H). 
13
C NMR (126 MHz, CDCl3) δC 172.7 (C), 169.2 (C), 168.4 (C), 161.3 (C), 1556.0 
(C), 153.1 (CH), 133.5 (C), 131.0 (CH), 130.9 (CH), 127.7 (CH), 126.7 (C), 111.6 
(CH), 109.7 (C), 96.9 (CH), 45.5 (CH2), 12.8 (CH3). 
IR (neat) 1738 (m, νC=O), 1335 (m, νAr-N), 1178 (m, νC-O) cm
-1
. 
6- carboxytetraethylrhodamine 58: 
Rf: 0.22 in 10:89.5:0.5 MeOH:DCM:TEA 
HPLC: 6.99 min (method 4). Purity ≥ 99% by ELSD detection. 
m/z (ES
+
): C29H30N2O5 calculated 486.56, found 487.2 [M+H]
+
 (80%).  
m/z (HRMS, ES
+
): C26H31N2O5 calculated [M+H]
+ 
487.22275, found 487.22260.  
1
H NMR (500 MHz, MeOD) δH 8.41 (d, J = 8.2 Hz, 1H, Ar-H), 8.38 (dd, J = 8.2, 1.3 
Hz, 1H, Ar-H), 7.98 (d, J = 1.1 Hz, 1H, Ar-H), 7.14 (d, J = 9.5 Hz, 2H, Ar-H), 7.04 




(dd, J = 9.5, 2.4 Hz, 2H, Ar-H), 6.99 (d, J = 2.3 Hz, 2H, Ar-H), 3.69 (q, J = 7.1 Hz, 
8H, Alkyl-H), 1.31 (t, J = 7.1 Hz, 12 H, Alkyl-H). 
13
C NMR (126 MHz, MeOD) δC 168.0 (C), 167.8 (C), 159.9 (C), 159.5 (C), 157.3 
(C), 136.6 (C), 136.1 (C), 135.5 (CH), 132.9 (CH), 132.4 (CH), 115.7 (CH), 114.9 
(C), 97.4 (CH), 12.9 (CH2), 7.8 (CH3). 














5-Carboxytetraethylrhodamine 57 (195 mg, 0.40 mmol), DMAP (244 mg, 2.0 mmol) 
and TEA (278.2 µL, 2.0 mmol) were dissolved in dry DCM (20 mL). DSC (205 mg, 
0.80 mmol) was added and the reaction stirred at room temperature for 1 h. Reaction 
completion was confirmed by TLC. The reaction was quenched using AcOH (229 
µL, 4.0 mmol) and without concentrating the solution was loaded onto an 
equilibrated column and eluted with 1% AcOH in acetone to afford pure the pure  
5-Rho-SE-50 (198 mg, 85%) or 6-Rho-SE-51 (89 mg, 87%) as dark pink solids. 
5-Rho-SE-50:  




Rf: 0.27 in 89.9:2 DCM:MeOH:AcOH 
HPLC: 6.44 min (method 4). Purity ≥ 99% by ELSD detection. 
m/z (HRMS, ES
+
): C33H34N3O7 calculated [M+H]
+ 
584.23913, found 584.23840.  
1
H NMR (500 MHz, CDCl3) δH 8.85 (d, J = 1.1 Hz, 1H, Ar-H), 8.29 (dd, J = 8.0, 1.7 
Hz, 1H, Ar-H), 7.29 (dd, J = 8.0, 0.5 Hz, 1H, Ar-H), 6.87 – 6.80 (m, 2H, Ar-H), 6.56 
– 6.53 (m, 4H, Ar-H), 3.44 (q, J = 7.1 Hz, 8H, Alkyl-H), 2.94 (s, 4H, Alkyl-H), 1.22 
(t, J = 7.1 Hz, 12H, Alkyl-H). 
13
C NMR (126 MHz, CDCl3) δC 172.7 (C), 169.2 (C), 168.4 (C), 161.3 (C), 156.0 
(C), 153.1 (C), 135.2 (CH), 133.5 (C), 130.9 (CH), 130.9 (CH), 127.8 (CH), 126.7 
(C), 111.6 (CH), 109.7 (C), 96.9 (CH), 45.5 (CH2), 25.9 (CH2), 12.8 (CH3). 
6-Rho-SE-51: 
Rf: 0.31 in 89.9:2 DCM:MeOH:AcOH 
HPLC: 6.45 min (method 4). Purity ≥ 99% by ELSD detection. 
m/z (HRMS, ES
+
): C33H34N3O7 calculated [M+H]
+ 
584.23913, found 584.23910.  
1
H NMR (500 MHz, CDCl3) δH 8.32 (m, 2H, Ar-H), 7.86 (t, J = 1.1 Hz, 1H, Ar-H), 
6.99 (d, J = 9.3 Hz, 2H, Ar-H), 6.66 (dd, J = 9.3, 2.4 Hz, 2H, Ar-H), 6.61 (d, J = 2.4 
Hz, 2H, Ar-H), 3.49 (q, J = 7.3 Hz, 8H, Alkyl-H), 2.87 (s, 4H, Alkyl-H), 1.25 (t, J = 
7.1 Hz, 12H, Alkyl-H). 
13
C NMR (126 MHz, CDCl3) δC 172.7 (C), 169.2 (C), 168.5 (C), 161.3 (C), 156.7 
(C), 153.9 (C), 141.7 (C), 131.8 (CH), 131.5 (CH), 130.1 (CH), 129.7 (CH), 127.5 
(C), 112.5 (CH), 111.4 (C), 96.6 (CH), 45.7 (CH2), 25.6 (CH2), 12.8 (CH3). 
 
 




Chapter 4 compounds 




To aminomethyl ChemMatrix resin (40 mg, 1.0 mmol.g
-1
) was attached Fmoc rink 
linker and amino acids using Oxyma (protocol P5). After final Fmoc removal 
(protocols P7), 5-carboxyfluorescein diacetate N-succinimidyl ester was attached and 
the compound cleaved from the linker using TFA (protocols P9 and P13) and 
purified via semi-preparative HPLC (method 6) (2.1 mg, 3% yield over 17 steps).  
HPLC: 2.43 min (method 4). Purity ≥ 99% by ELSD detection. 
MALDI-TOF: C61H90N15O13 calculated [M+H]
+












NLS Probe 2 - 62 
 
To aminomethyl ChemMatrix resin (50 mg, 1.0 mmol.g
-1
, particle size 35-100 mesh) 
was attached Fmoc rink linker and amino acids using Oxyma (protocols P5 and P7). 
After final Fmoc removal (protocols P7), the amine was acylated and the compound 
was cleaved from the linker using the HFIP (protocols P8 and P12). To the resulting 
compound (5 mg, 1 eq) was added a solution of Oxyma in DMF (44 µL, 0.07 M, 1 
eq) and left stirring for 10 min. DIC (0.49 µL, 1 eq) was added to the solution and 
left stirring for a further 5 min. 5-Aminofluorescein (1.32 mg, 1.2 eq) and  
TEA (0.5 µL, 1 eq) were added to the solution and the reaction left stirring for 1.5 h. 
All protecting groups were then removed using TFA (protocol P13). The compound 
was purified using semi-preparative HPLC (method 6). The desired product was 
obtained (1.1 mg) in 28% yield for the last step (2% yield over 19 steps).  
HPLC: 10.81 min (method 4). Purity ≥ 99% by ELSD detection. 
MALDI-TOF: C62H92N15O13 calculated [M+H]
+








NLS Probe 3 - 65 
To aminomethyl ChemMatrix resin (40 mg, 1.0 mmol.g
-1
) was attached Fmoc rink 
linker and N-Fmoc-8-aminooctanoic using Oxyma (protocols P5 and P7). After 
Fmoc removal, the isocyanate 4 was attached and Dde groups removed (protocols 
P5, P7, P3 and P4). Amino acids were coupled using Oxyma and after final Fmoc 
removal, 5-carboxyfluorescein diacetate N-succinimidyl ester was attached 
(protocols P7, P7 and P9). The compound was cleaved from the linker using TFA 
(protocol P13) and purified via semi-preparative HPLC (method 6) (14.0 mg, 9 % 
yield over 22 steps). 
HPLC: 3.33 min (method 4). Purity ≥ 99% by ELSD detection. 
MALDI-TOF: C205H306N48O44 calculated [M+H]
+
 4146.9133; found = 4147.4131. 
 




NLS Probe 4 - 67 
 
1,8-Diaminooctane was attached to the activated 2-chlorotrityl linker ChemMatrix 
resin (50 mg, 0.65 mmol.g
-1
) (protocols P1 and P2). The isocyanate 4 was then 
attached and the Dde groups removed (protocols P3 and P4). Amino acids were 
coupled using Oxyma and after final Fmoc removal the amine was acylated 
(protocols P5, P7 and P8). The compound was cleaved from the linker using HFIP, 
and the resulting compound coupled to 5-carboxyfluorescein diacetate N-
succinimidyl ester (protocols P12 and P14). Protecting groups were removed using 
TFA (protocol P13) and purified via semi-preparative HPLC (method 6) (2.0 mg, 
yield 2% over 21 steps). 
HPLC: 2.68 min (method 4). Purity ≥ 99 % by ELSD detection. 
MALDI-TOF: C169H295N48O34 calculated [M+H]
+ 
3541.2752; Found = 3541.2616. 
 




In vitro/ex vivo studies 
Flow cytometry analyses were carried out on a Becton Dickinson (BD) FACS  
Canto II using the FlowJo Version 7.6.3 software for data analysis.  
Microscopy studies were performed on Leica fluorescence microscope under 
bright light, 488 nm (fluorescein) and 543 nm (rhodamine). 
Confocal microscopy was performed on a Leica SP5 Confocal using the Zeiss 
510 Meta for digital acquisition and ImageJ for image analysis. 
 Ninety-six well plates were analysed on a microplate reader Synergy H1 
Reader using the Gen 5 (1.11). 
Jurkat cell culture: Jurkat cells were cultured in complete Roswell Park 
Memorial Institute (RPMI) media (RPMI 1640 (Gibco/Invitrogen), supplemented 
with 10% fetal bovine serum, 1% L-glutamine, 100 units/mL penicillin, 100 μg/mL 
streptomycin, complete RPMI) at 37 °C and 5% CO2. Cells were cultured in T-75 
flasks (Nunc) until 80% confluency before being prepared by centrifugation at 350 ḡ 
for 5 min for further analysis. Cellular experiments were carried out with cells 
passaged between 4- and 20-times. 
T cells plating: 
To purified CD4
+
 T cells, six aliquots of 8 x10
5
 cells per mouse sample were taken 
and re-suspended in 500 µL of PBS. One probe per aliquot was incubated for 10 min 
at 37 °C at a concentration of 5 µM made from a 5 mM DMSO stock solution. One 
aliquot per mouse was left probe-free. The reaction was stopped by adding cold 
complete RPMI media. Cells were washed twice to ensure complete excess probe 




removal. Each cell experiment was re-suspended in complete RPMI media, halved in 
two and plated onto a 96-well plate pre-coated with anti CD3/28. The plate was 
incubated at 37 °C and 5% CO2 and analysed using flow cytometry (BD  
FACS-Canto II using FlowJo Version 7.6.3 software for data analysis) after 48 h and 
72 h as well as imaged under a Leica DM IRB fluorescence microscopy. 
Flow cytometry on T cells:  
T cells were labelled with two fluorescent antibodies: CD4-PE (clone GK 1.5) and 
CD3-APC (17A2) for fluorescein based studies and CD4-APC (clone GK 1.5) and 
CD3-FITC (17A2) for rhodamine based studies. The cells were also treated with FC 
block (clone 2.4G2). Controls for flow cytometry included: (1) Non-stained control, 
(2) CD4-PE and CD3-APC markers, (3) CD4-APC and CD3-FITC markers. 
Jurkat cells experiment 
Jurkat cells were divided into aliquots of 6 x10
5
 cells in PBS. The cells were 
incubated with the probes at two concentrations 5 µM and 1 µM for 10 min at 37 °C 
and 5% CO2. The reactions were quenched with cold complete RPMI media, and 
washed twice with complete media. The cells were grown at 37 °C and 5% CO2 for 6 
days with the media being replaced with fresh media every two days. Aliquots of 
each experiment were analysed at day 0, 2, 3 and 6 using Flow cytometry (BD 
FACS-Canto II using FlowJo Version 7.6.3 software for data analysis). Unlabelled 
cells were used as control and each experiment was carried out in duplicate. 
Human neutrophil blood-preparation protocol: Sodium citrate tribasic 
dehydrate (4 mL of 3.8% in water) was added to human blood (40 mL) and 




centrifuge at 350 ḡ for 20 min. The top layer was discarded and to the remaining 
layer, 6 mL of dextran [6g Dextran 500 in 100 mL of 0.9% NaCl] was added and 
made up to 50 mL with sodium chloride (0.9% in water). The resulting solution was 
then mixed and allowed to sit for 20 min. The top layer was taken, made up to 50 mL 
with sodium chloride (0.9% in water) and centrifuged down (350 ḡ for 6 min). The 
supernatant was removed, and the cell pellet was re-suspended in 3 mL of the 55% 
Percoll
TM
. In a 15 mL falcon tube, was layered 3 mL of 68% Percoll
TM
 on top of 3 
mL of 81% Percoll
TM
. The 55% Percoll
TM
 cell suspension was then layered on top of 
the 68% Percoll
TM
 layer. The resulting three layers were centrifuged at 720 ḡ for 20 
min. The first layer containing monocyte and the excess liquid of the second layer 
were discarded. The neutrophil layer at the interface of the second and third layer, 
was isolated and washed twice using 50 mL of PBS and centrifuged down at 350 ḡ 
for 6 min. Neutrophils were re-suspended at 10 × 10
6
 cells/mL in complete IMDM 
media (phenol red free IMDM media, 1% L-glutamine, 25 mM hepes). 
Confocal experiment on human neutrophils: 
Neutrophils fixation: cover slips were immersed in fibronectin for 10 min. 
Fibronectin was removed and the coverslips washed twice with 2 mL of PBS. To the 
resulting coated fibronectin coverslips were added 2 mL of IMDM media and 100 
µL of neutrophils using a wide mouth pipette tip. The neutrophils were allowed to sit 
for 15 min at 37 °C and 5% CO2. Media was removed and replaced with the 
following options: 
For non activated neutrophil studies: 1 mL of a 10 µM solution of probe in 
IMDM (stock solution of each probes were made at 1 mM using 10% DMSO in 




PBS, and aliquots diluted with IMDM media to obtain a final probe concentration of 
10 µM). 
For activated neutrophil studies: 750 µL of a 10 µM solution of probe in 
IMDM, and then 250 µL of a solution of 10 µM of ionophore A23/87 to activate the 
neutrophils. 
For activated neutrophils with elastase inhibitor studies: 750 µL of a 10 µM 
solution of probe in IMDM with 1 µL of inhibitor Sevelestat, and then 250 µL of a 
solution of 10 µM of ionophore A23/87 to activate the neutrophils.  
Live cells were imaged using confocal microscopy performed on a Zeiss lsm 510 
meta confocal microscope under bright light, 488 nm (fluorescein) and 543 nm 
(rhodamine), Zeiss 510 Meta software was used for digital acquisition and ImageJ 
for data analysis. 
Kinetic studies: 
In a 96 well plate were prepared solutions of the probe in acetate buffer at ten 
different concentrations in triplicates: 50 µM, 25 µM, 12.5 µM, 6.25 µM, 3.13 µM, 
1.56 µM, 0.78 µM, 0.39 µM, 0.20 µM, 0.10 µM. Human sputum elastase (EC 
3.4.21.37, No. SE563 obtained from Elastin products company, inc) was prepared in 
acetate buffer and used at a final concentration of 17 nM. The fluorescence increase 
was measured using an excitation wavelength of 485 nm and emission wavelength of 
528 nm, every 17 sec at 37 °C for 30 min. The experiments were carried out on a 
microplate reader Synergy H1 Reader Serial Number: 253179. 




A standard curve of 5(6)-carboxyfluorescein was carried out using concentrations 
ranging from 25 µM to 2.4.10
-05 
µM (See appendices section). The equation of the 
straight line obtained from plotting the concentration against the fluorescence 
allowed us to convert the fluorescence of the kinetic experiments into concentrations.  
Using GraphPad prism software the slope of the initial linear phase of each curve 
was accurately calculated allowing us to generate the Michaelis Menten data. 
NLS Confocal experiment on A549: 
To fixed A549 cells in 8 well chambers were added a solution of 10 µM of the probe 
of interest in complete DMEM media (phenol red free DMEM media, 10% fetal 
bovine serum, 1% L-glutamine, 100 units/mL penicillin, 100 μg/mL streptomycin) 
and incubated at 37 °C and 5% CO2 for 1 h. Syto 82 orange fluorescent nucleic acid 
stain was then added to the cells at a concentration of 5 µM and incubated at 37 °C 
and 5% CO2 for 20 min. The media was then remove and replace with fresh media 
containing 10 µM of the probe, and imaged using confocal microscopy performed on 
a Zeiss lsm 510 meta confocal microscope under bright light, 488 nm (fluorescein) 
and 543 nm (rhodamine), Zeiss 510 Meta software was used for digital acquisition 
and ImageJ for data analysis. 
Confocal experiment on A549: 
To fixed A549 cells in 8 well chambers, were added a solution of 10 µM of the probe 
of interest in complete DMEM media (phenol red free DMEM media, 10% fetal 
bovine serum, 1% L-glutamine, 100 units/mL penicillin, 100 μg/mL streptomycin) 
and incubated at 37 °C and 5% CO2 for 15 h. The wells were imaged using confocal 




microscopy performed on a Zeiss lsm 510 meta confocal microscope under bright 
light, 488 nm (fluorescein) and 543 nm (rhodamine), Zeiss 510 Meta software was 
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